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ABSTRACT 
CHARACTERIZING THE EFFECT OF CJUN ON THE EXPRESSION OF OCT4 
VARIANTS, POTENCY AND CELL FATE OF MURINE EMBRYONIC STEM 
CELLS 
 
Kristine Teague 
 
 cJun is a transcription factor associated with proliferation and growth. Recent 
evidence has shown it plays a role in cell fate decision making of embryonic stem cells 
and correlates with changes in Oct4 expression, an important marker for pluripotency. 
There are multiple Oct4 isoforms that arise from alternative splicing and alternative 
translation. Oct4A is the variant most frequently associated with pluripotency, while 
evidence suggests that Oct4B variants have roles in potency as well as stress responses.  
 We aimed to study the effect of cJun over expression in murine embryonic stem 
cells on Oct4 gene expression through two methods: transient transfection of a pLVX 
cJun plasmid and treatment with nocodazole. We hypothesized that cJun expression 
would be increased with both of these methods and that these increases would affect Oct4 
gene expression, which would affect the expression of the potency markers Nanog and 
Sox2 and possibly the expression of germ layer markers Brachyury, Sox1, Gata6, and 
Gata4. The unphosphorylatable cJun mutant L40/42A was also transfected to assess the 
role of cJun transcriptional activity on these processes. Our results revealed a trend where 
increased cJun correlated with changes in Oct4 variant expression that correlate with 
 iii 
 
cJun transcriptional activity. Nanog expression appeared unaffected by transfection, but 
decreased with nocodazole treatment. Sox2 expression appeared to increase slightly with 
transfection, but remained relatively unaffected by nocodazole treatment. cJun 
overexpression through transfection increased endoderm markers Gata6 and Gata4, 
which correlates from other data in our laboratory that shows overexpression of cJun 
increases cardiomyocyte differentiation of mES cells (Brewer 2017). Further studies will 
better elucidate the relationship between cJun, the Oct4 variants, and their effect on 
potency and cell fate. 
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INTRODUCTION 
Cellular potency is the term used to describe the ability of undifferentiated cells to 
differentiate into multiple cell types. As cells become directed towards a particular cell 
fate, their potency decreases.  Embryonic stem cells (ESCs) are derived from the inner 
cell mass (ICM) of the blastocyst and have the ability to form all the cells of the 
organism, as evidenced by their ability to contribute to all the tissues of a chimeric 
organism when placed into a blastocyst (Martin 1981). Therefore, they are described as 
pluripotent. The pluripotency of ESCs make them useful in studying the molecular and 
cellular mechanisms of organismal development and disease. Through an understanding 
of these processes, cellular-based therapies can be developed to provide targeted 
treatment options (reviewed in Pan et al. 2002, Romito and Cobellis 2016, Chen et al. 
2017). 
Cellular potency is controlled by a complex network of molecular mechanisms 
that regulate gene expression, beginning with chromatin regulation. The open and varied 
structures of chromatin in ESCs lead to expression of genes necessary for the pluripotent 
state, in comparison to more differentiated cells (Meshorer et al. 2006, Efroni et al. 2008, 
Barrero et al. 2010). Additionally, ESCs are characterized as having increased expression 
of chromatin remodeling factors (Ho et al. 2009) and hypomethylated promoters which 
facilitate gene expression (Grabole et al. 2013). In addition to open and active promoter 
regions, expression of developmental genes, such as those involved in lineage 
commitment, are regulated by bivalent promoter regions that suppress gene expression, 
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while leaving the machinery poised for transcription. These regions are characterized by 
H3K27me3 and H3K4me3 modifications (Azuara et al. 2006, Bernstein et al. 2006) 
which are antagonistic histone modifications, the presence of CpG islands (Fouse et al. 
2008, Meissner et al. 2008), and the presence of RNA polymerase II at transcription 
initiation sites of many developmental genes (Guenther et al. 2007).  
The three main transcription factors involved in maintaining pluripotency are 
Oct4, Sox2, and Nanog (reviewed in Chambers and Smith 2004, Takahashi and 
Yamanaka 2006, Okita et al. 2007, Chen et al. 2017). Generally, the three proteins work 
together to regulate expression of their own genes as well as others important to 
maintaining pluripotency (reviewed in Shi and Jin 2010). They also occupy many of 
these bivalent regions in various combinations, which suggests that they regulate the 
repression of developmental genes (Boyer et al. 2005). While these three factors are the 
main transcription factors, they work in cooperation with each other, and other 
transcription factors, to form a regulatory network that maintains pluripotency and self-
renewal until a developmental signal initiates a differentiation program that changes the 
chromatin landscape (Wang et al. 2006, Pardo et al. 2010). Overexpression of the three 
together is sufficient for reprogramming terminally differentiated cells (Takahashi and 
Yamanaka 2006, Okita et al. 2007). Additionally, Oct4 is the only one which cannot be 
substituted with any other member of the Octamer binding protein family (reviewed in 
Jerabek et al. 2014). 
The Role of Oct4 in Pluripotency and Development 
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Oct4/Pou5f1 is part of the POU, or Pit-Oct-Unc, family of transcription factors 
and is essential for the maintenance and self-renewal of pluripotent stem cells. The 
protein consists of a POU specific DNA binding domain, POU homeodomain, and C-
terminal and N-terminal transactivation domains (reviewed in Shi and Jin 2010). 
Expression of the Oct4 protein is high in early development and is necessary for the 
pluripotency of the ICM during the blastocyst stage, as deletion of Oct4 in embryos 
during the transition from morula to blastocyst removes the ability of the embryo to 
differentiate toward primitive endoderm or epiblast tissues (Le Bin et al. 2014). Not only 
is Oct4 capable of actively maintaining potency through activation of potency genes, it 
also plays a role in lineage commitment and development. The loss of Oct4 results in the 
inability of the ICM to develop into the three germ layers required for development and 
instead becomes trophectoderm tissue (Nichols et al. 1998, Velkey and Sue O ’shea 
2003). Oct4 levels must be kept at specific levels to maintain potency (reviewed in Shi 
and Jin 2010). A less than two-fold over expression of Oct4 can lead to differentiation 
into primitive endoderm and mesoderm tissues, more specifically, derivatives of those 
germ layers, such as the cardiac cell lineage in mouse ESCs and embryos in the early 
stages of differentiation (Zeineddine et al. 2006, Rodriguez et al. 2007), while a reduction 
of Oct4 expression by one-half leads to trophoblast tissue (Niwa et al. 2000).  
 A balance of enhancing and inhibiting factors function in combination with each 
of the three core pluripotency transcription factors to facilitate the cell fate decision 
making process that enables differentiation (Boyer et al. 2005, reviewed in Jerabek et al. 
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2014). Oct4 has been shown to be a key factor this process.  When Oct4 is overexpressed 
in murine embryonic stem cells, it switches from the Sox2 promoter region to that of 
Sox17. This results in a change in chromatin structure from one that favors pluripotency 
to one that drives cells to mesoendoderm and ultimately cardiomyocyte-like cell fate 
(Aksoy et al. 2013, Abboud et al. 2015). Additionally, Oct4 regulates Fgf4 signaling 
which acts as a paracrine signal from ICM cells to the trophectoderm and directly 
activates expression of Gata6, predisposing it toward a primitive endoderm fate 
(reviewed in Jerabek et al. 2014). As a paracrine signal, Ffg4 initiates the upregulation of 
Sox17 and Gata4 in progenitor cells of the primitive endoderm, but the loss of Oct4 
causes a complete loss of Gata6 four days post coitum (dpc) and the Fgf4-dependent gene 
expression of primitive endoderm genes is compromised and only minimally rescued 
with exogenous Fgf4.  
Oct4 gene expression is regulated by a GC rich, TATA-less, and hypomethylated 
promoter which is critical to the maintenance and self-renewal of stem cells (Hattori et al. 
2004; Feldman et al. 2006; reviewed in Hackett and Surani 2012). As it is conserved over 
a number of mammalian species, regulation of its expression and how it correlates with 
the stages of development has been well studied in the murine system (reviewed in 
Jerabek et al. 2014). There are two enhancer elements, distal and proximal, which drive 
transcription of Oct4 in a tissue and developmentally specific manner. The proximal 
promoter is responsible for activity during the epiblast stage, while the distal enhancer 
functions prior to implantation and is then restricted to germ cell lineages following 
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implantation (reviewed in Jerabek et al. 2014). Multiple transcription factor proteins 
directly bind the Oct4 promoter to control its transcription and external factors such as 
leukemia inhibitory factor (LIF), Wingless-related integration site (Wnt), and TGF-
β/bone morphogenic protein (BMP) signaling influence Oct4 expression. BMP works 
with LIF synergistically to maintain potency through activation of the JAK/STAT3 and 
phosphophatidylinositol 3-kinase (PI3K)/ AKT signal pathways to activate Oct4 
transcription (reviewed in Jerabek et al. 2014). Oct4 transcription can also be increased 
through Wnt/ β-catenin signaling, which activates the TCF/LEF complex bound at three 
specific sequences in the Oct4 promoter (Li et al. 2012).  Examples of other molecules 
that regulate Oct4 transcription include steroidogenic factor-1, estrogen-related receptor b 
(Esrrb), Sall4, Tcf3, HIF, CDK2, and germ cell nuclear factor (GNFC) (reviewed in Shi 
and Jin 2010 and Jerabek et al. 2014).  
Oct4 activity is also regulated through mRNA splicing and alternative translation. 
The human OCT4 gene, POU5F1, can produce 3 different mRNAs through alternative 
splicing: OCTA, OCTB and OCT4B1. OCT4A is the main variant involved in 
pluripotency and typically expressed at higher levels than OCT4B in nuclei of pluripotent 
cells (reviewed in Wang and Dai 2010 and Jerabek et al. 2014). The OCT4B splice 
variant contains an internal ribosomal entry site (IRES) and a different start codon that 
allows it to produce 3 different gene products through alternative translation: OC4B-265, 
OCT4B-190 and OCT4B-164. These variants only differ in their N-terminal 
transactivation domains: OCT4B-190 and -164 do not have N-terminal transactivation 
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domains and OCT4-265 has a domain that differs from OCT4A. All of the OCT4B 
isoforms have a nuclear localization signal, however they tend to localize in the 
cytoplasm.  OCT4B-190 appears to respond to heat and cell stress and its overexpression 
protects against apoptosis following heat shock, while OCT4B-265 increases with 
genotoxic stress and is correlated with an increase in apoptosis (reviewed in Jerabek et al. 
2014). The OCT4B1 variant is a putative stemness marker, because its expression pattern 
is high in undifferentiated cells and decreases upon differentiation, mimicking OCT4A 
expression throughout development (Atlasi et al. 2008, Papamichos et al. 2009). This was 
demonstrated in 59 human ESC lines as well as a significant correlation with NANOG 
expression in undifferentiated cells and a strong negative correlation to genes upregulated 
upon differentiation (Atlasi et al. 2008, Papamichos et al. 2009).  
The mouse Oct4 homologue also produces Oct4A and Oct4B transcripts through 
alternative splicing. Cells in the neuroblastic layer of mice were found to express these 
Oct3/4 variants and to have both stem cell-like characteristics and those of differentiated 
neurons, providing a case for Oct4 expression in somatic tissues (Mizuno and Kosaka 
2008). Oct4B can be translated into multiple isoforms: Oct4B-247aa, Oct4B-190aa and 
Oct4B-164aa (Guo et al. 2012). Mouse Oct4B is very similar to the human OCT4B.  
Oct4B localizes in the cytoplasm, increases expression upon heat shock or oxidative 
stress and many of the amino acids in the N-terminal domain are identical to the human 
OCT4B N-terminal domain. The expression of various isoforms appears to correlate to 
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different environmental and developmental functions, however Oct4A seems to have a 
larger role in development and pluripotency. 
 
 
 More recently Liu et al. have demonstrated new transcript and protein variants in 
mouse Oct4B (2017). They observed the same Oct4A and Oct4B transcripts seen 
previously, with the addition of four other transcript variants (Figure 2). These new 
Oct4B mRNAs vary in the number and size of introns retained. Oct4B and Oct4B’ differ 
in the number of nucleotides spliced out of intron 1, while the remaining variants contain 
intron 2 (Oct4B1), introns 2 and 4 (Oct4B2), or introns 2 through 4 (Oct4B3). Because 
NIH3T3 cells do not produce endogenous Oct4 variants, protein variants were assessed 
through transient transfection with four constructs: Oct4b (pOb), Oct4b’ (pOb’), Oct4b2 
(pOb2), and Oct4b3 (pOb3). Protein analysis after 36 hours post transfection showed that 
Oct4b’ produced one 189aa band, while the others produced three bands: Oct4B-246aa, -
221aa and -189aa (Figure 2). Interestingly, these three bands are produced for Oct4b2 
Figure 1. Mouse Oct4 produces two mRNA transcripts (A.) and four protein 
isoforms (B. and C.). These figures were originally published in Guo et. al 2012. 
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and 3 despite premature stop codons. Additionally, the 163aa product previously 
described by Mizuno and Kosaka (2008) was not seen in this study. 
9 
 
 
 
B. C. 
A. 
Figure 2: Mouse Oct4 produces six mRNA transcripts and multiple protein 
products. A. Analysis of mouse chromosomal 17 sequence shows the different exons 
for each variant in color and indicated by the bars to the right of the sequence. Oct4A 
mRNA consists of exon 1-5 with text in blue. The beginning sequence for Oct4b is 
highlighted in red text and the beginning of Oct4b’ is highlighted in purple text. All 
exons and variants can also be determined by the bars to the right of the sequence. B. A 
graphical representation of the six mRNA transcripts. C. Western blot analysis of 
Oct4B protein from transiently transfected NIH3T3. Oct4b’ (pOb’)constructs produced 
one band at 189aa, while Oct4b (pOb), Oct4b2 (pOb2), and Oct4b3 (pOb3) each 
produce three bands at 189aa, 221aa, and 246aa (Liu et al. 2017). 
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Regulation of Oct4 Expression Through c-Jun 
 cJun is a dimeric transcription factor belonging to the activator protein 1 (AP-1) 
family. An immediate early gene, transcription of cJun is increased by mitogen 
stimulation (reviewed in Curran and Franza 1988).  The transcriptional activity of cJun is 
increased through phosphorylation of serine-63 and serine-73 (reviewed in Shaulian and 
Karin 2002, Czaja 2003) primarily performed by mitogen activated protein kinase 
(MAPK) family member Jun N-terminal kinase (JNK) (reviewed in Shaulian and Karin 
2002 and Eferl and Wagner 2003). cJun expression can also be increased through 
alternative translation pathways activated through cytoskeletal disrupting drugs such as 
nocodazole (Polak et al. 2006, Blau et al. 2012). Nocodazole increases cJun protein 
expression in cell culture, but this is independent of mitogen activation and does not 
increase cJun transcript levels (Polak et al. 2006). Rather, the alternative translation of 
cJun was shown to be regulated by an IRES in the cJun 5’ UTR (Polak et al. 2006).  
cJun has been shown to provide a variety of functions during cellular cycling and 
development. It regulates cellular progression from G to S1 of the cell cycle, apoptosis, 
and oncogenic transformation (reviewed in Jochum et al. 2001and Shaulian and Karin 
2002). Additionally, cJun plays a role in development. cJun deficient mice, which contain 
a mutation in the cJun locus, die 11-12 days post coitum (dpc) (Johnson et al. 1993) and 
these fetuses present with defects in the interventricular septum of the heart and 
incomplete separation of aorta and pulmonary artery, suggesting lethality is a result of 
impaired cardiovascular function (Eferl et al. 1999). cJun deficient ESCs were able to 
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contribute to all tissues in a chimeric mouse, except for the liver (Hilberg et al. 1993) and 
cJun deficient fetal hepatocytes have an increased incidence of apoptosis and decreased 
proliferation (Eferl et al. 1999). Loss of cJun in hepatocytes, postnatally, did not result in 
any abnormalities other than impaired regeneration following a partial hepatectomy 
(Behrens et al. 2002). cJun was also expressed almost ubiquitously throughout 
development, however heightened expression was noted within rapidly dividing cells 
(Wilkinson et al. 1989). A more recent study showed cJun expression promoted axon 
growth in central nervous system neurons, independently of other target genes thought to 
be essential for cJun to promote axon growth (Lerch et al. 2014). It has also been 
demonstrated that cJun inhibits the expression of potency genes such as Nanog, Sall4, 
and Oct4 in mouse embryonic stem cells, while upregulating genes that lead to endoderm 
lineage like Gata6 and Gata4 (Liu et al. 2015). 
 cJun transcriptional activity can regulate Oct4 transcription and transient 
expression of cJun has shown a decrease in pluripotency in mESCs (Liu et al. 2015, 
Veluscek et al. 2016, Hosawi et al. in prep). Our lab has located a putative AP-1 binding 
site within the proximal promoter of the Oct4 gene.  Using a polyclonal antibody 
generated from the first 138 amino acids of the human Oct 4 protein, we have shown an 
increase in endogenous phosphorylated cJun. This correlates with an increase in protein 
containing amino acids from the Oct4A and Oct4B isoforms in murine embryonic stem 
cells (mES) cells treated with anisomycin, a JNK activator, or transfected with a GFP 
cJun construct (Hosawi 2016). Overexpression of cJun in mES cells prevented the 
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formation of insulin secreting clusters (Hosawi 2016), increased Gata4 protein 
expression, and correlated with increased cardiomyocyte differentiation (Brewer 2017). 
Our lab also demonstrated that cJun can up-regulate transcription of the Oct4 promoter 
through luciferase assays (Brewer 2017). Chromatin immunoprecipitation data shows 
cJun physically associates with the Oct4 promoter (Varkey unpublished data). In light of 
these data, we are interested in determining whether cJun can affect Oct4 variant 
expression and if that affects the expression patterns of genes involved in murine 
embryonic stem cell potency and cell fate decision making required in early embryonic 
development. 
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Statement of Aims 
This project aims to elucidate the role of cJun in regulating Oct4 expression and 
its effects on the regulation of genes involved in pluripotency and early embryonic 
development. Data generated by others in our lab with an Oct4 variant-specific antibody 
suggested that cJun increased expression of the Oct4A and Oct4B, however it remains 
unclear whether this occurs at the transcriptional or translational control. If 
overexpression of cJun changes the expression of Oct4 in murine embryonic stem cells, 
we predict cell fate decision making could be affected.  Finally, it is unknown if 
Figure 3. Immunoblot of nuclear protein from cells treated with SP600125, 
Anisomycin, and nocodazole. A. Following nocodazole treatment for 2h and 
4h, cJun protein expression is increased. While Oct4A expression also increases 
upon treatment with nocodazole for 2h and 4h, Oct4all protein expression shows 
little change. B. Immunoblot data for a different replicate which shows an 
increase in cJun following 2h treatment with nocodazole, however no changes in 
cJun expression are seen at 4h. Additionally, Oct4all and Oct4A expression do 
not appear to change drastically, despite the differences in cJun expression at 2h 
and 4h. 
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cytoskeletal-induced translation of cJun occurs in murine embryonic stem cells and, if so, 
whether or not this mechanism affects Oct4 transcription and/or protein expression. We 
intend to address these questions through the following aims: 
Specific Aim #1: Define the role of cJun in the regulation of mRNA expression of Oct4 
and other pluripotency genes.  
In order to test if cJun affects Oct4 expression at the transcriptional level, we have 
characterized the levels of Oct4 mRNA in mES cells that were transiently transfected 
with GFP cJun, the transcriptionally inactive cJun mutant GFP cJun L40/42A, and GFP 
alone.  RNA was isolated from these cells, reverse transcribed to cDNA and screened by 
qPCR to see if there was a change in the transcript levels of Oct4A by using primers 
designed to amplify exon 1. We amplified Oct4B variants using primers for exon 2 
(Oct4all_E2), which do not amplify Oct4A sequences, and all Oct4 variants using 
primers for exon 5 (Oct4all_E5), which is present in all variants. Primers specific to the 
GFP cJun construct, pLVXcJun primers, were designed and used to establish levels of the 
ectopically expressed cJun mRNA above that of endogenous cJun ( Appendix B). The 
expression of each gene was normalized to Gapdh and compared, using relative 
quantification, for each sample: no treatment (NT), empty vector (GFP), and a 
transcriptionally inactive cJun (L40/42) controls, as well as the GFP cJun overexpression 
construct. Because we have previously demonstrated that an increase in cJun correlates to 
an increase in a mixed pool of protein containing Oct4A, Oct4B or Oct4B1, we expected 
to see an increase in these transcripts if this correlation was transcriptionally regulated. If 
increases in cJun and/or Oct4 variants change the potency of the cells, we might also see 
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a modification in the mRNA levels of Sox2 and Nanog. Therefore, qPCR was used to 
quantify those transcripts as well. 
Specific Aim #2: Determine the effect of cJun overexpression on germ layer gene 
expression 
  If overexpression of cJun changes the amount of Oct4 protein in murine 
embryonic stem cells, we predicted the cells may be directed towards a specific cell fate. 
As a specific level of Oct4 protein is necessary to maintain pluripotency or initiate 
differentiation, an increase in Oct4 would lead to a change in expression of genes 
associated with germ layer formation, which we assessed through RT-qPCR. The cDNA 
generated from the mESCs transfected with GFP, GFP cJun, or GFP cJun L40/42A was 
analyzed for the expression of germ layer markers Brachyury (mesoderm), Gata6 
(endoderm), Gata4 (endoderm), and Sox1 (ectoderm).  The gene expression for all genes 
and each sample was normalized to Gapdh and quantified using relative quantification.   
Specific Aim #3: Determine if nocodazole treatment increases cJun protein in murine 
embryonic stem cells and if that increase correlates with changes in Oct4 protein 
expression 
Immunoblot data in our lab demonstrates the addition of nocodazole to mESCs 
can increase the phosphorylation of cJun. It can also affect the levels of Oct4 protein, 
however the mechanism is unknown and our result is inconsistent (Figure 3).We are 
curious to know if the increased Oct4 isoforms observed are associated with the increased 
expression of cJun, or if the alternative translation pathway induced through cytoskeleton 
disruption would also affect Oct4 translation. As a preliminary test, we addressed the 
effect of nocodazole on Oct4 levels through RT-qPCR and immunocytochemistry (ICC) 
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assays. Cells were previously treated with nocodazole for two hours and stored for later 
RNA extraction. RNA was extracted from nocodazole treated cells, NT, and DMSO 
controls and evaluated for changes in the Oct4 transcript. In addition, mESCs were 
treated with nocodazole and stained for cJun, Oct4 and Oct4A/B. While by no means a 
conclusive test, if increased cJun expression co-localizes with increased Oct4A 
expression, that would support a hypothesis that cJun overexpression is related to Oct4 
expression. 
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METHODS 
Basic Cell Culture of J1 Murine Embryonic Stem Cells 
Murine Embryonic cell line J1 (American Type Culture Collection (ATCC) (Cat# 
SCRC1010, Manassas, VA) were grown on a feeder layer of murine embryonic 
fibroblasts treated with mitomycin C (MEFs, CytoSpring LLC, Mountain View, CA) and 
plated at 30,000 cells/cm2 in culture dishes that have been pre-treated with a 0.1% gelatin 
solution (STEMCELL Technologies Inc, Vancouver, BC, Canada). Prior to mESC plating, 
these MEFs were incubated in MEF media consisting of 10% fetal bovine serum (Life 
Technologies, Carlsbad, CA) in 1X DMEM base media (Life Technologies, Carlsbad, 
CA).  Mouse ESCs were grown in mESC media containing DMEM, 15% FBS, 1% 
2.0mM L-Alanyl-L-glutamine (STEMCELL Technologies Inc, Vancouver, BC, Canada), 
0.1 mM 2-mercaptoethanol (Sigma- Aldrich, Louis, MO), 1% 1X nonessential amino 
acids (Life Technologies, Carlsbad, CA), and 50 units/ml LIF (EMD Millipore, Temecula, 
CA).  All cells were incubated at 37℃ and 5% CO2 and passaged at approximately 50% 
confluency.  Each time cells were passaged, cells were washed with sterile DPBS (Life 
Technologies, Carlsbad, CA), treated with 0.05% trypsin to remove adhered cells, spun 
down at 1400 x g for 5 minutes at room temperature and resuspended in warmed fresh 
mESC media.  Cells were quantified and viability assessed with a trypan blue assay and 
all cells were plated at 30,000cells/cm2. 
. 
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Immunocytochemistry 
MEFs were plated to glass coverslips coated in 2 μg/ml fibronectin (Sigma- 
Aldrich, Louis, MO) and incubated in MEF media described above until mESC plating. 
mESCs were plated on MEF coated coverslips at 30,000 cells/cm2 and incubated in 
mESC media at 37℃ and 5% CO2 for 48h. Following this incubation, cells were treated 
with nocodazole at a final concentration of 5µg/ml or a 0.1% DMSO control for 2 or 4 
hours. After drug treatment, cells were rinsed with DPBS and fixed in 0.5ml 4% 
paraformaldehyde in PBS per well for 5 minutes at room temperature.  After fixation, the 
cells were washed five times in two-minute incubations with DPBS.  The cells were then 
permeabilized with 2 ml of 1% NP-40 (Sigma- Aldrich, Louis, MO) in DPBS in each well 
and incubated at room temperature for 30 minutes.  Next, blocking buffer containing 
1.0% normal goat serum (Thermo Fisher Scientific, Waltham, MA) and 0.1% TX-100 
(Sigma- Aldrich, Louis, MO) in DPBS was added to each well and incubated at room 
temperature for 30 minutes.  The first primary antibody was added to their respective 
wells (Table 1): Anti-cJun (Abcam119944), Anti-Oct4 (Abcam ab19857) or Anti-Oct4A 
(Cell Signaling Technologies 2840S).  A no primary control coverslip was treated with 
blocking solution instead of primary antibody and these cells were incubated at room 
temperature for 1h. The coverslips were washed three times, for 5 minutes each, with 
DPBS and the appropriate secondary antibody listed in Table 1 was added at the 
appropriate dilution to each well and incubated for 60 minutes at room temperature, in 
the dark. Coverslips were washed three times with DPBS, five minutes each, in the dark 
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and then placed back in block solution and incubated in the dark at room temperature for 
30 minutes. Following this incubation, the second primary antibody was added to the 
appropriate wells, with block solution added to the no primary control, and incubated in 
the dark at room temperature for 60 minutes. While remaining in the dark, the cells were 
rinsed three times with DPBS, five minutes each, and the appropriate secondary antibody 
added (Alexafluor 488 or Texas Red, Table 1) (Molecular Probes, Life Technologies, 
Grand Island, NY). 
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Table 1. Antibodies and dilutions used in ICC analysis.  Stem cells treated with 
nocodazole will be incubated with cJun and either Oct4 or Oct4A/B antibodies. This 
determined the relative expression of Oct4 or Oct4A/B in reference to cJun within the 
same cell.  
 
Antibody Company and 
catalog number 
Dilution 
Mouse anti-cJun Abcam1ab 19944 1/200 
Rabbit anti-Oct4 Abcam ab19857  1/200 
Rabbit anti-Oct4A/B Cell Signaling 
Technologies 2840S 
1/200 
Alexafluor 488: Goat 
IgG to mouse IgG 
Life Technologies 
A11001 
1/500 
Texas Red: Goat IgG 
to rabbit IgG 
Life Technologies 
T6391 
1/200 
 
Cells were incubated in the dark at room temperature for 60 minutes and rinsed 
three times with DPBS, five minutes each. Each coverslip was then be mounted on a 
glass slide with 7μl of DAPI mounting media (Molecular Probes, Life Technologies, 
Grand Island, NY) and allowed to cure overnight at room temperature, covered.  The 
coverslips were then surrounded by nail polish, allowed to dry, and stored covered at 4°C 
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for long term storage.  The cells were imaged using a Zeiss Axio Observer Z1 
microscope.  
RNA Isolation, cDNA Generation and Quantitative PCR 
RNA was isolated from several stored samples, mentioned above, according to a 
protocol adapted from the Fisher Bio Reagents SurePrep TrueTotal RNA Purification Kit 
(Cat# BP2800-50).  Briefly, cells were lysed with 350μl lysis solution containing beta-
mercaptoethanol and vortexed for 15 seconds.  200μl of 95-100% ethanol was added and 
each sample vortexed for 10 seconds.  The lysate solution was placed on column and 
centrifuged at 14000 x g for 1 minute.  The flow-through was discarded and 400μl of 
wash solution was applied to the column and centrifuged at 14000 x g for 1 minute.  The 
flow-through was discarded and this step was repeated once more.  A third wash was 
done with 400μl of wash solution and spun down at 14000 x g for 2 minutes to dry the 
column.  The collection tube was discarded with the flow-through and the column placed 
in a 1.5ml Eppendorf tube. Elution buffer (50μl) was added directly to the column and 
incubated at room temperature for one minute. This was centrifuged at 200 x g for two 
minutes, followed by a one-minute spin at 13,000 x g.  The eluent was placed back on 
column and the step repeated. The concentration of the final product was determined 
using the NanoDrop 1000 Spectrophotometer (ThermoScientific, Waltham, MA).  The 
RNA product was stored at -80℃ until needed. 
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Following extraction, 300ng of mRNA product was treated with 0.5-1U DNaseI 
(Invitrogen, Carlsbad, CA) for 15 minutes at room temperature and 1µl 25mM EDTA 
was added. The DNaseI was heat inactivated at 65°C for 10 minutes. This product was 
transcribed to cDNA using Applied Biosystems High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA) and a sample with reverse 
transcriptase enzyme (+RT) as well as a control sample without enzyme (–RT), were 
created for each sample according to the manufacturer’s protocol. Once the reactions 
were loaded in the appropriate tubes, the reaction was run in a thermocycler with the 
following parameters: 25℃ for 10 minutes, 37℃ for 2 hours, 85℃ for 5 minutes and 
held at 4℃ until collection.  These samples were stored at -20℃ for future use. 
 The PCR cocktail was prepared for a final volume of 20μl containing SYBR 
Advantage qPCR Master Mix at a final concentration of 1X, a ROX-LSR reference dye 
(Clonetech, Mountain View, CA) and 0.2μM of the appropriate primers (Table 2). Oct4A 
and Oct4 variant expression were assessed with a probe-based assay (IDT). Cocktails 
were made according to manufacturer’s protocol. Following this, samples were treated 
the same as the other primer sets. Template or water was added to the cocktail in its 
respective tube. cDNA samples were run in triplicate and three no template controls 
(NTCs) created for each gene. A control cDNA sample was serially diluted to create 
standard curves for each gene and the efficiency of each primer set was determined. The 
PCR reaction was set up using the software for the Applied Biosystems 7300 qPCR 
Machine.  The reaction was carried out as follows: initial denaturation for 2 minutes at 
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95℃, denaturation at 95℃ for 40 cycles at 5 seconds each, annealing at 60℃ for 40 
cycles at 30 seconds each, extension at 70℃ for 40 cycles at 30 seconds each and 
dissociation at 95℃ for 15 seconds, 60℃ for 1 minute, 95℃ for 15 seconds and 60℃ for 
15 seconds.  The annealing temperature varied depending on the primer set (
 Appendix B). The results were analyzed with Applied PCR 7300 Analysis 
software. 
To analyze the PCR product, a 2-3% agarose gel was prepared and run with 1X 
TAE Buffer.  Loading dye was added to each PCR product to give a final concentration 
of 1X.  Half of this volume was loaded into subsequent wells and run at 70 volts for one 
to two hours, stained in ethidium bromide and rinsed in dH2O. Stain and rinse incubation 
times varied depending on the amount of agarose. The gel was imaged using the 
AlphaImagerHP MultiImage II (Alpha Innotech).   
Data Analysis 
Gene expression data for each gene was normalized to Gapdh expression and 
relative expression determined using a modified Michael W. Pfaffl equation which 
accounts for varied primer efficiencies (Pfaffl 2004). These data are given as Mean ± 
Standard Error (SE). Additionally, dissociation curves were produced for each sample to 
account for the decreased specificity of SYBR. This was not performed for the probe-
based assays. The significance of these data was determined by performing a one-way 
ANOVA in R Studio for each gene. Tukey’s HSD analysis was performed on ANOVA 
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results which produced p-values less than 0.05. All ICC images were processed 
identically to ensure they were comparable and co-localization was assessed using the 
ZEN imaging software from Carl Zeiss (Zeiss).   
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RESULTS 
Characterizing cJun Over Expression in mESCs Transiently Transfected with PLVX-
GFPcJun and PLVX-GFP L40/42A  
If cJun regulates Oct4 variant expression, one would expect ectopic 
overexpression of the cJun protein would affect Oct4 mRNA levels. Furthermore, if cJun 
regulates transcription of the Oct4 mRNA directly, cells in which the transcriptionally 
inactive cJun mutant L40/42A is expressed should have a different effect on Oct4 mRNA 
levels when compared to control cells than those overexpressiong wild type cJun.  To test 
these hypotheses, pLVXGFP, pLVX GFP cJun and the pLVX GFP cJun L40/42A mutant 
plasmids were transfected into mES cells with Lipofectamine 3000,  plated onto gelatin 
and harvested 36 hours post transfection, after transfection efficiency was confirmed by 
flourescent microscopy of GFP. mRNA was isolated and converted to cDNA. To identify 
for biological variation, the transfections were performed in triplicate 3-4 times.  
As  immunoblot data from our lab demonstrates that endogenous cJun is 
expressed in J1 mES cells cultured on irradiated MEFs in LIF media (Figure 3 and not 
shown) and transfection efficiency was relatively low (< 20%), we developed two qPCR 
primer sets for cJun mRNA quantitation. One was directed to transcripts produced by the 
cJun loci in the genomic DNA as well as those from the pLVXcJun and L4042 plasmids 
(cJun primers). The second set was designed such that the forward primer was 
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complimentary to pLVX sequences 5’ of the cJun coding sequence in the plasmid 
(pLVXcJun primers).  
When cJun cDNA was quantified using the cJun primers and compared to cJun 
transcript levels in untransfected control cells, the expression levels normalized to NT 
showed a 41.45±8.44 fold increase in cells transfected with the pLVX cJun plasmid and a 
32.81±14.54 fold increase in those transfected with pLVXL4042. These were 
significantly higher than expression levels seen in cells transfected with pLVXGFP, 
which had a fold change of 1.13±0.34. When the pLVX cJun primers were used to 
quantify cJun cDNA levels, the fold change expression of pLVX cJun transcripts 
compared to untransfected controls was 650.93±314.5 for cJun, 154.3±61.53 for 
L40/42A and 4.92±3.22 and for GFP. Unlike the products produced by the cJun primers, 
only one band of the appropriate size was generated in these reactions. (Figure 4 and 
Table 2 )  
The slightly increased expression of cJun  in the cells expressing GFP alone 
suggested the plasmid transfection appeared to have an effect on gene expression in 
general. Knowing the GFP plasmid did not contain endogenous cJun, we evaluated the 
levels of cJun normalized to GFP expression. The GFP normalized cJun  expression data 
generated with the cJun primers were 38.96±16.16 and 31.97±13.18 for cells transfected 
with cJun plasmid and L40/42 respectively. The GFP normalized cJun expression data 
generated with the pLVXcJun primers was 199.28±52.73 and 61.87±29.9 for cJun and 
L40/42 transfected cells, respectively. A one-way ANOVA was performed on these data 
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and found that cJun expression normalized to NT alone varried significantly (p<0.05, 
n=3, F(3,8)= 6.306). Tukey’s HSD determined that cJun expression varied significantly 
between cJun transfected cells and NT or GFP samples (p<0.05, n=3,).  One way 
ANOVA did not show any statistically significant difference between treatments with 
cJun data normalized to GFP. Plasmid expression normalized to both NT and GFP were 
significant by one-way ANOVA, p<0.05 and p<0.01 for NT(F(3,12)= 3.673) and GFP 
normalized (F(2,9)= 9.747), respectively (n=4).Tukey’s HSD showed that plasmid 
expression normalized to NT was not as significant with p<0.1(n=4) for cJun transfected 
cells compared to NT or GFP samples. Plasmid expression normalized to GFP were 
significant for cJun samples compared to NT (p<0.05) and GFP (p<0.01) by Tukeys HSD 
test (n=4). Gel analyses of these samples showed that cJun and L40/42 transfected 
samples produced multiple bands, however dissociation curve analysis did not always 
produce multiple peaks for cJun primers (Figure 4 and Table 2). Although the pLVXcJun 
primers produced multiple dissociation peaks, gel analysis demonstrated only one 
prominent band at the predicted size of 70bp (Figure 4). Because of this, we utilized 
pLVX expression as an analog for transfection efficiency and thus a marker for cJun over 
expression.  
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Figure 4. cJun primers produced multiple bands upon agarose gel analysis while 
pLVX primers produced singular bands. A. A representative image of both cJun 
and pLVXcJun PCR products. Dissociation curve analysis of cJun primers produced 
multiple peaks and multiple bands on the gel (lanes 4-6). One sample did produce a 
dissociation curve with one clear peak, but still showed multiple bands on the gel 
(lanes 1-3). This could be due to amplification of the transfected plasmid resulting in 
single strands. The pLVXcJun primers always produced one band at 70bp, but almost 
all replicates had dissociation curves with 2 peaks (lanes 10-12 and 13-15). Two 
replicates had one dissociation peak, but only one was analyzed on a gel and also 
produced one band at 70bp (lanes 7-9). The second dissociation peaks were small and 
could be due to GC or AT rich regions in the sequence that would cause a small 
secondary peak once it dissociated. B. An example of the multiple bands seen with 
cJun primers. Here more distinct bands can be seen and each sample had dissociation 
curves with multiple peaks. Lanes are labeled with replicate date, then sample as 
follows: 1-3) 32 L40/42, 4) 32 cJun, 5) 510L40/42, and 6) 530 L40/42. These data are 
also summarized in table 2.  
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Table 2. List of cJun and pLVXcJun samples, Ct value, approximate dissociation 
temperatures, number of each triplicate affected and number of bands present on 
agarose gel. Only samples transfected with the L40/42 cJun mutant or GFP cJun 
produced variable data. Upon gel analysis, all cJun samples showed multiple bands for all 
triplicates, however dissociation curve analysis did not always show multiple peaks for 
those triplicates. Ct values were all within 1 Ct value, demonstrating that expression was 
not greatly affected by the additional bands. In contrast to cJun expression, amplification 
with plasmid primers produced dissociation curves with multiple peaks, but only one 
band upon gel analysis. The multiple dissociation peaks were inconsistent and did not 
affect all triplicates. Asterisk indicates samples not used in data analysis. 
 
Replicate Treat-
ment 
 Primer 
set 
Average 
Ct value 
Approximate 
dissociation 
temperature 
(ºC) 
# of 
triplicate 
Bands 
present 
Fold 
change 
express-
ion 
normal-
ized to 
NT or 
GFP 
1 GFP cJun 14.29 85 3 No gel run NT: 
262.99* 
1 L40/4
2 
cJun 18.08 87 3 No gel run NT: 
8.65*, 
GFP:0.0
3* 
1 cJun 
(plasm
id) 
cJun 16.61 87 3 No gel run NT: 
30.57*, 
GFP:0.1
3* 
2 GFP cJun 23.12 85 3 No gel run NT: 0.57 
2 L40/4
2 
cJun 17.67 84 and 87 3 118bp, 
290bp, 500bp 
NT: 
29.96,  
GFP: 
53.01 
2 cJun 
(plasm
id) 
cJun 18.45 84 and 87 1 118bp, 
190bp, 290bp 
NT: 
48.79,  
GFP: 
86.35 
3 GFP cJun 20.85 85 3 No gel run NT: 1.1 
3 L40/4
2 
cJun 21.77 84 and 87 1 118bp, 
multiple 
bands of 
indeterminant 
size in the 
190-700bp 
range 
NT: 9.17 
GFP:8.3 
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Replicate Treat-
ment 
 Primer 
set 
Average 
Ct value 
Approximate 
dissociation 
temperature 
(ºC) 
# of 
triplicate 
Bands 
present 
Fold 
change 
express-
ion 
normal-
ized to 
NT or 
GFP 
3 cJun 
(plasm
id) 
cJun 16.88 85 and 87 3 Multiple 
bands of 
indeterminant 
size between 
118-190bp 
NT:24.6
2 
GFP:22.
27 
4 GFP cJun 20.95 85 3 No gel run NT:1.75 
4 L40/4
2 
cJun 16.69 84 and 87 1 118bp, bands 
of 
indeterminant 
size ≥ 500bp 
NT:59.3
1 
GFP:33.
98 
4 cJun 
(plasm
id) 
cJun 17.28 85 3 bands of 
indeterminant 
size between 
118-190bp 
and 300-
500bp 
NT:50.9
5 
GFP: 
29.19 
1 GFP pLVXc
Jun 
40 78, 84 3 No gel run NT: 0.77 
1 L40/4
2 
pLVXc
Jun 
34.53 82 3 No gel run NT: 
21.81 
GFP:28.
98 
1 cJun 
(plasm
id) 
pLVXc
Jun 
32.47 82 3 No gel run NT:119.
64 
GFP: 
168.51 
2 GFP pLVXc
Jun 
40 79, 89, 88 3 No gel run NT: 0.72 
2 L40/4
2 
pLVXc
Jun 
33.20 82 3 70bp NT: 
107.84 
GFP:149
.2 
2 cJun 
(plasm
id) 
pLVXc
Jun 
32.37 82 3 70bp NT:239.
43 
GFP: 
331.28 
3 GFP pLVXc
Jun 
38.1 71,76,86 3 No gel run NT:3.89 
3 L40/4
2 
pLVXc
Jun 
30.61 76 and 82 1 70bp NT:174.
46 
GFP: 
44.85 
31 
 
 
Replicate Treat-
ment 
 Primer 
set 
Average 
Ct value 
Approximate 
dissociation 
temperature 
(ºC) 
# of 
triplicate 
Bands 
present 
Fold 
change 
express-
ion 
normal-
ized to 
NT or 
GFP 
3 cJun 
(plasm
id) 
pLVXc
Jun 
30.76 76 and 82, 76 
and 90 
2 70bp NT: 
740.68 
GFP: 
190.42 
4 GFP pLVXc
Jun 
36.642 
 
70,78 3 No gel run NT:14.3
4 
4 L40/4
2 
pLVXc
Jun 
32.68 76 and 82 1 70bp NT:313.
41 
GFP: 
21.86 
4 cJun 
(plasm
id) 
pLVXc
Jun 
31.07 76 and 82 2 70bp NT: 
1504.03 
GFP: 
104.89 
 
 
Overexpresion of cJun Has a Varied Effect on mRNA Expression of Oct4A and 
Pluripotency Markers Nanog and Sox2 
Having varified transfection of PLVXcJun and PLVXL4042/A leads to over 
expression of cJun in each of  the four experimental replicates, we were interested in 
measuring Oct4 cDNA levels to determine the effect of cJun overexpression on this 
important pluripotency marker. As the level of Oct4 protein affects cellular potency, we 
also determined gene expression for two other pluripotency factors, Nanog and Sox2. 
Primer sets were validated by amplifying both cDNA from mESCs and DNA, correct 
amplicon size confirmed, and sequenced for correct amplicon sequence. The gels for this 
can be seen in Figure 5 and produced the following amplicon sizes: 230bp (Gapdh), 
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118bp (cJun), 70bp (GFPcJun plasmid), 364bp (Nanog), 207bp (Sox2), and 111bp 
(Oct4A). 
  When normalized to untransfected cells (NT), Oct4A cDNA was 1.52±0.3 fold 
higher in pLVX cJun transfected cells , 1.62±0.86 fold higher in PLVX L40/42 
transfected cells and 1.36±0.4 fold higher in cells transfected with PLVX GFP. When 
normalized to Oct4A levels in cells expressing GFP, fold expression was 1.29±0.31 and 
1.5±0.9 higher for cells expressing with cJun and L40/42 respectively. Nanog gene 
expression was 1.54±0.7, 1.22±0.43, and 1.17±0.42 for cJun, L40/42, and GFP 
transfected cells respectively. GFP normalized data were 1.15±0.28 and 1.02±0.17 for 
cJun and L40/42 respectively. Similarly, Sox2 gene expression was 2.20±1.27, 3.61±2.75, 
and 1.45±0.67 for cJun, L40/42, and GFP transfected cells respectively. GFP normalized 
data were 1.31±0.32 and 1.72±0.62 for cJun and L40/42 respectively (Figure 5). One-
way ANOVA analyses of NT and GFP normalized data produced no statistically 
significant difference between treatment for any gene (p>0.05, n=4). The affect of cJun 
over expression is variable and may be due to variations in transfection efficiency in each 
replicate. While not statistically signifcant, as changes in Oct4 expression of 1.5 fold 
have been demonstrated by others to have biological affects (Niwa 2000), the increases 
seen in the presence of cJun and L4042 are expected to effect potency. Therefore, it is 
possible the mild increases in Nanog and Sox2 expression could also have biological 
implications.  
  
33 
 
 
 
  
A. 
B.
34 
 
 
 
 
Because the Oct4 gene produces multiple mRNA variants, we used a previously 
validated probe-based assay (Integrated DNA Technologies, Skokie, Illinois) to see if 
transfection with cJun affected variant expression.  Oct4A gene expression was measured 
with a primer and probe set designed to bind  exon 1, which is only present in the Oct4A 
Figure 5. Overexpression of cJun affects expression levels of Sox2, and Oct4A. A. 
A graph of NT normalized expression data for Oct4A, Nanog and Sox2. B. Graph of 
the same expression data normalized to GFP. C. Table showing gene expression of 
cJun and plasmid (pLVXcJun primers) to demonstrate cJun over expression and 
plasmid transfection efficiency. Because transfection efficiency varied between 
replicate and between treatments, plasmid expression will be used as a marker for 
overexpression, in place of cJun expression. D-I. Gels of PCR amplified cDNA to 
confirm the correct amplicon size for each gene: Gapdh (D), Sox2 (E), Nanog (F), 
GFPcJun plasmid (G), cJun (H), and Oct4A using primers for SYBR analysis (I). 
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mRNA variant. These primers did not amplify genomic DNA under the experimental 
conditions, despite the presence of the forward and probe sequences in exon1 and the 
reverse in exon 2. The intron 1 sequence is a little over 2,300bp, which cannot be 
amplified in the 30sec annealing and elongation steps. The primer probe combination 
used to analyze exon 2 recognizes five Oct4B variants, Oct4b’, Oct4b, Oct4b1, Oct4b2, 
and Oct4b3:.  These primers did not initially amplify cDNA from mESCs, but did 
amplify from genomic DNA as well as  cDNA generated from embryoid bodies (EBs). 
Finally, we used a primer and probe set which amplified exon 5, which is conserved over 
all Oct4 mRNA variants. The exon 5 primers were designed to not amplify genomic 
DNA with a probe that spans an intron sequence, ensuring an trace amounts of genomic 
contamination would not be quantified (Figure 7). These data were normalized to 
untransfected (NT) and then to GFP in the same manner as the previous genes. When 
normalized to NT expression levels, Exon 1 expression was 1.73 ±0.36 fold higher for 
cJun transfected cells, 0.96±0.35 for the L40/42 and 1.58±0.63 for GFP transfected cells. 
The fold change for GFP normalized data was 1.35±0.19 and 0.94±0.47 for cJun and 
L40/42 respectively. Exon 2 expression was 2.71±1.1, 16.91±16.5, and 1.23 ±0.72 for 
cJun, L40/42, and GFP transfected cells. Expression for GFP normalized data were 
5.97±4.73 and 74.21±73.51 for cJun and L40/42, respectively. Exon 5 gene expression 
was 1.51±0.25 for cJun transfected cells and 1.33±0.58 and 0.69±0.28 for the L40/42 and 
GFP controls. GFP normalized data were 4.13±2.2 and 6.5±5.2 for cJun and L40/42, 
respectively.  
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Dispite the large differences in Oct4 expression levels seen in the presence of 
cJun and L40/42, a one-way ANOVA of these data, both NT and GFP normalized, did 
not show any significant difference in fold change between treatment for any gene 
(p>0.05, n=4) (Figure 6), likely due to the large standard error among the averaged 
samples. To see if the difference in Ct values were the result of irregular qPCR 
amplification among the replicates, these samples were run on agarose gels to confirm 
the expected base pair sizes of 111bp, 91bp, and 135bp for exon 1, exon 2, and exon 5 
respectively (Figure 5 A-C). We found that exon 2 and exon 5 produced additional bands 
and smears, while exon 1 produced this result to a lesser extent. Upon analysis of new 
transcript sequences the new expected base pair band became 91bp (Oct4b’), 296bp 
(Oct4b2 and Oct4b3), and 297bp (Oct4b and Oct4b1) for exon 2. New expected sizes for 
exon 5 were 135bp for Oct4A, Oct4b’, Oct4b, and Oct4b1 and 274bp for Oct4b2 and 
Oct4b3. Additional bands seen by agarose gel were between 100-900bp for exon 2, with 
the brightest bands at 296bp, indicating amplification of either Oct4b2, Oct4b3, Oct4b, or 
Oct4b1. Bands for exon 5 were between 135-800bp, with bright bands at the expected 
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135bp, indicating less expression of Oct4b2 and Oct4b3. Exon 1 produced only one band 
on the gel at the expected 111bp size (Figure 7 and  
  
Figure 7. Exon 1 primers produce one amplicon, while exons 2 and 5 produce 
multiple bands from various Oct4B variants. A. Agarose gel of exon 1. Only one band 
is seen at the expected 111bp. There do appear to be very faint bands below these, which 
are assumed to be primer dimers or other noise, as they also appear in the –RT samples. 
Lanes 1-24 are triplicates for each treatment of one replicate and are consistent between 
treatments.  Lanes 4-6 are NT, GFP are lanes 10-12, L40/42 are lanes 16-18, and cJun 
transfected samples are lanes 21-24. The remaining lanes are the corresponding –RT 
samples. B. Agarose gel of Exon 5. NT samples are in lanes 4-6., GFP in 10-12, L40/42 
in 16-18, and cJun samples in lanes 21-24. You can see multiple bands in all samples. C. 
Agarose gel of exon 2. Lanes 4-6 are NT samples, 10-12 are GFP, 16-18 are L40/42, and 
21-24 are cJun samples. Multiple bands can be seen in GFP, L40/42 and cJun samples. 
The bands in the L40/42 and cJun treatments are more abundant and varied in size. 
Additionally, cJun and L40/42 samples contain the largest band at about 1000bp and 
900bp, respectively. These upper bands, denoted by the two white arrows, are faint but 
distinct. D. Agarose gel analysis of all the Oct4 primers off cDNA (lane2) and genomic 
DNA (lane 3). Exon 1 did not amplify in the no template control (NTC) sample (lane 1) 
or the genomic DNA. Similarly, exon 5 did not amplify the NTC (lane 7) or genomic 
DNA (lane 9), but did amplify cDNA (lane 8). Exon 2 only amplified the genomic DNA 
(lane 6). Because of this EB cDNA was used. E. Agarose gel analysis of exon 2 primers 
amplifying cDNA from embryoid bodies (EBs). Lane 1 shows the primers amplify 
genomic DNA and lane 3 shows they will amplify cDNA from EBs. Lane 2 shows the 
primers will not amplify the –RT sample. 
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Table 3). Because exon1 primers only produced one band and the probe sequence 
removes background qPCR signal, we assumed the extra bands seen on the gel for exon 2 
and exon 5 only affect the calculated expression data if the bands contain the probe 
sequence and are variations on the known Oct4B variants.  
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Figure 6. cJun over expression increases gene expression of Oct4B variants. A. NT 
normalized graph of exons 1, 2, and 5. Exon 2 data were much larger than exon 1 or 5 so 
it was removed and graphed separately (C. and F.). B. NT normalized data of exons 1 
and 5. C. NT normalized data for exon 2. D. GFP normalized data for all exons. E. GFP 
normalized data for exons 1 and 5. F. GFP normalized data for exon 2. G. Table of 
plasmid expression from figure 5, for reference. 
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Figure 7. Exon 1 primers produce one amplicon, while exons 2 and 5 produce 
multiple bands from various Oct4B variants. A. Agarose gel of exon 1. Only one band 
is seen at the expected 111bp. There do appear to be very faint bands below these, which 
are assumed to be primer dimers or other noise, as they also appear in the –RT samples. 
Lanes 1-24 are triplicates for each treatment of one replicate and are consistent between 
treatments.  Lanes 4-6 are NT, GFP are lanes 10-12, L40/42 are lanes 16-18, and cJun 
transfected samples are lanes 21-24. The remaining lanes are the corresponding –RT 
samples. B. Agarose gel of Exon 5. NT samples are in lanes 4-6., GFP in 10-12, L40/42 
in 16-18, and cJun samples in lanes 21-24. You can see multiple bands in all samples. C. 
Agarose gel of exon 2. Lanes 4-6 are NT samples, 10-12 are GFP, 16-18 are L40/42, and 
21-24 are cJun samples. Multiple bands can be seen in GFP, L40/42 and cJun samples. 
The bands in the L40/42 and cJun treatments are more abundant and varied in size. 
Additionally, cJun and L40/42 samples contain the largest band at about 1000bp and 
900bp, respectively. These upper bands, denoted by the two white arrows, are faint but 
distinct. D. Agarose gel analysis of all the Oct4 primers off cDNA (lane2) and genomic 
DNA (lane 3). Exon 1 did not amplify in the no template control (NTC) sample (lane 1) 
or the genomic DNA. Similarly, exon 5 did not amplify the NTC (lane 7) or genomic 
DNA (lane 9), but did amplify cDNA (lane 8). Exon 2 only amplified the genomic DNA 
(lane 6). Because of this EB cDNA was used. E. Agarose gel analysis of exon 2 primers 
amplifying cDNA from embryoid bodies (EBs). Lane 1 shows the primers amplify 
genomic DNA and lane 3 shows they will amplify cDNA from EBs. Lane 2 shows the 
primers will not amplify the –RT sample. 
45 
 
 
Table 3. Summary of bands present on agarose gel for exon 1, exon 2, and exon 5 
and the corresponding treatment condition they were located. A comparison of 
expected amplicon sizes with the amplicons seen on agarose gel. While many bands were 
expected for the Oct4B variants, there were additional bands that were not expected. 
These may be additional sequences as of yet unidentified. They may or may not have 
contributed to the expression data, as dissociation curves cannot be run on probe assays. 
 
Primer set Expected bands Bands present Treatment 
Exon 1 1 band-111bp 1 band- 111bp All 
Exon 2 Oct4b’: 91bp 
Oct4b2 and 3: 296bp  
Oct4b and b1: 297bp 
296 or 297bp 
350bp 
900bp 
1000bp 
multiple indistinct bands 
of indeterminate size in 
the range of 100-296bp. 
All 
cJun and L40/42 
L40/42 
cJun 
GFP, L40/42, and 
cJun 
Exon 5 Oct4A, Oct4b’, Oct4b 
and Oct4b1: 135bp  
Oct4b2 and 3: 274bp 
135bp 
300bp 
350bp  
400bp 
 500bp 
All 
 
 
cJun and L40/42 
cJun and L40/42 
 
cJun Over Expression Increases Gene Expression of Endoderm Markers 
As the changes Oct4 variant expression and the increased Sox2 cDNA levels 
presents in cJun and L40/42 overexpressing cells are expected to affect potency, we 
measured transcript levles  of germ layer markers  Brachyury, Sox1, Gata4, and Gata6  to 
determine whether a shift in gene expression of pluripotency factors would initiate 
expression of these germ layer markers and if there was a bias towards one germ layer or 
another. Expression of the mesoderm marker Brachyury was 1.02±0.38, 0.83±0.06, and 
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1.24±0.35 fold higher for cJun, L40/42, and GFP transfected cells. GFP normalized data 
were 1.04±0.42 and 0.88±0.27 for cJun and L40/42 samples. The ectoderm marker, Sox1, 
showed 1.14±0.48, 1.49±0.44, and 1.05±0.37 fold changes in expression for cJun, 
L40/42, and GFP, respectively. Expression for cJun and L40/42 samples normalized to 
GFP were 1.01±0.4  and 3.66±2.76, respectivley. Gata4 expression, a marker for 
endoderm, was 1.39±0.37, 1.39±0.61, and 0.97±0.12 for cJun, L40/42, and GFP samples. 
GFP normalized data were 1.41±0.34 and 1.43±0.61 for cJun and L40/42, respectively. 
Primative endoderm marker, Gata6, produced a fold change of 2.54±0.69 in cJun 
transfected cells and 2.3±1.12 and 1.52±0.31 for L40/42 and GFP transfected samples, 
respectively. These data normalized to GFP were 1.63±0.39 and 1.46±0.53 for cJun and 
L40/42 (Figure 8). One-way ANOVA analyses of NT and GFP normalized data did not 
produce statistical significance between treatment for any gene (p>0.05, n=4). While 
samples were not analyzed by gel electrophoresis, they were validated in the same 
manner as previously mentioned and produced the expected amplicon sizes: 134bp 
(Sox1), 117bp (Brachyury), 225bp (Gata4), and 182bp (Gata6) (Figure 8). 
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Nocodazole Increases cJun Gene Expression and Effects Oct4 Variant Gene Expression 
in mESCs 
Nocodazole treatment of cells was shown to increase in cJun protein expression 
through an alternative translation pathway without a proportional increase in mRNA 
expression (Polak et al. 2006, Blau et al. 2012, unpublished data Sprowles Lab). 
Furthermore, the cJun proteins produced through this mechanisms have different 
transcriptional targets than those generated from increased transcription (Blau et al. 
2012). We used SYBR qPCR assays to quantify cDNA levels of cJun, Oct4A, Nanog, 
Figure 8. Figure 8. Over expression of cJun increases expression of Gata6 
and Gata4. A. NT normalized expression data. B. GFP normalized expression 
data. C. Table of plasmid expression for reference. D. Agarose gel of Sox1, 
which produced the expected 134bp band. E. Agarose gel of Brachyury, which 
produced the correct 117bp amplicon. F. Agarose gel of Gata4 (lane 1) and Gata6 
(lane 2), which produced 225bp and 182bp bands respectively. 
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Sox2. Overall, cJun expression was increased with nocodazole treatment (Table 4). 
However, the range of cJun cDNA between replicates was highly variable, so a one-way 
ANOVA performed on these data and was not statistically significant (p> 0.05, n=3). The 
large variation in expression data (data not shown) could be due to the small replicate 
number of 3, but because DMSO also exhibits a varied effect on expression, the variation 
may be due to a dosage effect from both DMSO and nocodazole. Nonetheless, there are 
trends observed when relative levels of cJun are taken into account.There is a general 
decrease in Nanog expression with decreasing cJun for both nocodazole and DMSO 
treatment. Expression of Sox2 does not seem to have any relation to cJun expression due 
to nocodazole or DMSO. Expression of Oct4 using SYBR varies wildy with nocodazole 
treatment, while the same primers in the probe assay does not (Table 4). Interestingly, 
Oct4A expression does not vary greatly in DMSO samples, despite one replicate 
containing multiple dissociation peaks and 2 bands upon gel analysis (Figure 9). The 
additional band between 1200bp and 1500bp could be a product of a currently unknown 
mechanism as a reaction to DMSO and may be dose dependent as no other replicate 
treated with DMSO produced the same effect. The expression pattern for Nanog, Sox2, 
and Oct4A was similar with DMSO normalized data, however the variance is slightly 
decreased.  
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Table 4. Increases in cJun expression associate with increases in Oct4 variants and 
decreases in Nanog expression. A. NT normalized data for each gene assayed by both 
SYBR and probe-based assays. B. DMSO normalized data for each gene evaluated by 
STBR and probe-based assays. For both tables, expression values associated with 
nocodazole treated samples are in aqua, while the values associated with DMSO 
treatment are in peach. 
 
A. 
Replicate Treatment cJun Oct4A SYBR Nanog Sox2 Oct4A 
exon 1 
Oct4B 
exon 2 
Oct4all 
exon 5 
1 NT 1 1 1 1 1 1 1 
1 DMSO 0.29 3.45 0.74 3.94 2.00 2.41 1.82 
1 Nocodazole 50.67 538.76 0.35 3.53 3.24 3.08 30.03 
2 NT 1 1 1 1 1 1 1 
2 DMSO 1.20 2.88 0.91 1.20 1.41 2.38 7.55 
2 Nocodazole 51.84 4.72 0.36 0.75 3.72 0.39 2.85 
3 NT 1 1 1 1 1 1 1 
3 DMSO 0.69 6.98 2.89 0.57 0.19 1.08 0.23 
3 Nocodazole 1.84 1335.16 1.89 0.46 0.24 1.07 0.30 
B. 
Replicate Treatment cJun Oct4A SYBR Nanog Sox2 Oct4A 
exon 1 
Oct4B 
exon 2 
Oct4all 
exon 5 
1 DMSO 1 1 1 1 1 1 1 
1 Nocodazole 169.89 155.79 0.47 0.89 1.62 1.27 16.48 
2 DMSO 1 1 1 1 1 1 1 
2 Nocodazole 43.10 1.63 0.40 0.62 2.63 0.16 0.37 
3 DMSO 1 1 1 1 1 1 1 
3 Nocodazole 2.65 191.17 0.65 0.80 1.23 0.99 1.31 
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Similar to transfection data, we assessed the expression of the Oct4 mRNA 
variants using a probe-based assay. Generally, when there was an increase in cJun 
expression from either DMSO or nocodazole, there was an increase in Oct4 expression. 
DMSO appears to affect Oct4B variants, while nocodazole appears to have an increased 
effect on Oct4A versuses the other variants. These tentative relationships appear to be 
dose dependant, as intermediate cJun levels produce an intermediate effect on Oct4 
expression (Table 4). Additionally, when Oct4A increases the Oct4B variants decrease. 
These trends are weak, but are potentially affected by the low sample size and the 
multiple bands seen by agarose gel electrophoresis. Like the transfected samples, 
mulitple bands were seen for the Oct4 variants. Exon 1 primers produced the expected 
111bp band and 2 additional bands at 200bp and 400bp. The additional bands are only 
Figure 9. DMSO produces multiple bands in one replicate amplified by Oct4A 
primers. Exon 1 primers used in sybr assays produced multiple dissociation peaks (data 
not shown) and produced multiple bands on a gel. The expected 111bp band is clearly 
seen in all samples, but there is a large and bright band between 1200-1500bp. This does 
not appear to affect the expression data for this replicate, as it is similar to another 
replicate with similar cJun expression. Lanes 1-3 are NT, 4-5 DMSO, and lane 7 is one 
triplicate of the nocodazole sample for the same replicate. Both NT and nocodazole 
samples produced one clear dissociation peak. 
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seen in DMSO and nocodazole samples for all replicates and indicate an unaticipated 
effect of both DMSO and nocodazole on Oct4A expression.  Exon 5 produced multiple 
bands in all treatments, however NT only contains the expected 135bp and 274bp bands. 
Additional bands seen in DMSO and nocodazole treated samples were approximately 
350bp and 450bp. This could be due to differences in splicing as yet to be defined. 
Similar to exon 1, exon 2 produced multiple unexpected bands in DMSO and nocodazole 
samples. NT samples produced one clear band at approximately 296-297bp, which 
corresponds to the Oct4b and Oct4b1-3 variants. The expected 91bp band for Oct4b’ may 
be the faint bands below, but could also be primer dimers as this band is also seen 
occasionally in the –RT and NTC samples, which showed no amplification on qPCR 
analysis. DMSO samples produced the 296-297bp band as well, but also produced a 
550bp band and multiple bands between 250-90bp. Nocodazole produced the expected 
band as well as more clear bands at 250bp and 90bp (Figure 10).These variations in band 
sizes could explain the variation in expression data as band intensities and number of 
additional bands varied slightly between each replicate.  
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Because Oct4A is essential in maintaining potency of stem cells and because 
variations in protein expression can direct cell fate, indentifying whether or not the 
changes in gene expression are seen as changes in protein expression in the same cell will 
further support the hypothesis that cJun directly regulates the expression of Oct4A. The 
use of ICC allowed for localization of the either cJun and Oct4A or cJun and Oct4all (all 
Oct4 protein variants) to the individual cell level. If the signals were co-localized, this 
would indicate that cJun is regulating expression of Oct4 variants and suggests that 
increases in cJun correlate to increases in Oct4 within the same cell, which may lead to 
changes in potency and cell fate. ICC analysis of these data showed variation in cJun, 
Figure 10. DMSO and nocodazole treatment have an effect on Oct4 variant 
expression. A. A representative agarose gel of exon 1. DMSO and nocodazole treatment 
have a clear effect on Oct4A expression, producing bands that were not expected at 
about 300bp and 400bp. Lane 3-6 are NT, Lanes 10-12 and 16-18 are DMSO and 
nocodazole samples respectively. Remaining lanes are corresponding –RT samples 
which did not amplify on qPCR analysis. B. A representative gel of exon 5. Multiple 
bands are seen in all samples, however additional bands that were unexpected were seen 
only in DMSO and nocodazole samples. Two bands are expected for exon 5 primers at 
135bp and 274, which cover all known Oct4 variants. These are seen in all samples, but 
additional bands at 350bp and 450bp are seen in DMSO and nocodazole treated samples. 
Lanes 4-6 are NT, lanes 10-12 are DMSO and lanes 16-18 are nocodazole samples. 
Remaining lanes are corresponding –RT samples. C. Representative gel of exon 2. Like 
exon 1, only one band is seen in the NT sample approximately 297bp, indicating any of 
the four Oct4B variants, Oct4b and Oct4b1-3. Oct4b’ at 91bp may or may not be the 
faint lower bands seen. DMSO and nocodazole samples have clear bands at approximate 
297bp, but also have additional bands. Nocodazole produces multiple bands around 
250bp and 90bp, while DMSO produces these and others of indeterminate size in that 
range of 250-90bp. DMSO produces an additional clear band at approximately 550bp. 
Lanes 4-6 are NT, lanes 10-12 are DMSO, and lanes 16-18 are nocodazole samples. 
Remaining lanes are corresponding –RT samples.  
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Oct4A/B and Oct4all protein expression between and within replicates. Despite this, 
there are some trends that suggest cJun and Oct4 expression are affected by nocodozole.  
Generally, nocodazole appears to increase cJun and Oct4A/B expression, with 
overlap within the bright spots (Error! Reference source not found.).  Like the qPCR 
data, there is an increase in DMSO treatment, but nocodazole increases the trend, with 
the largest cellular co-localization of cJun and Oct4 A/B/B’ occuring 4h post-nocodazole 
treatment. Where bright Oct4A/B/B’ points are seen, there are corresponding spots of 
cJun signal, however the Oct4A/B/B’ spots do appear to be smaller (Error! Reference 
source not found.). Analysis of these spots using the Zeiss co-localization software 
seemed to support these findings. The replicate data were pooled (n=3) and analysed as a 
number of spots out of the total identified. There were approximately 1-3 cell colonies 
per image and increases in co-localized spots did not appear to increase with colony 
number. For cJun and Oct4A images, there were an average of 2.05 ± 0.29 colonies for 
NT, 1.94 ± 0.47 for 2h DMSO treatments, 2.1 ± 0.23  colonies for 4h DMSO, and 2.04 ± 
0.23 colonies and 1.67 ± 0.17 colonies for 2h and 4h nocodazole treatments, respectively. 
When cJun protein expression was compared to that of all Oct4 protein isoforms within 
the cells, there are few spots identified per colony of cells imaged, but the ratio of 
identified co-localization to total number of colonies evaluated for each treatment 
gradually increases with nocodazole treatment. The greatest difference in this ratio is 
seen between NT and 4h nocodazole treated samples, however the increase is not as large 
when looking at co-localizations that had both a strong Pearson’s coefficient (≥0.1) and a 
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strong Mander’s coefficient (≥0.98) or higher, as defined by Zinchuk et. al (2007).  
Aproximately 48% of all co-localized spots had at least a strong Pearson’s and a strong 
Mander’s in NT samples, but only 51% were seen with samples 4h post nocodazole 
treatment. Interestingly, 2h post nocodazole treatment had 81% of co-localized spots with 
these criteria (Table 5). This indicates that nocodazole treatment increases cJun co-
localization with Oct4A, but a stronger degree of co-localization is seen in 2h nocodazole 
samples compared to the 4h samples. 
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Figure 11. Nocodazole treatment increases co-localization of Oct4A/B or Oct4all 
with cJun. A-E. Comparison of cJun expression with Oct4A/B expression across all 
treatments to determine the effect of nocodazole on cJun expression as well as the co-
localization of cJun to Oct4A. Generally, there is a decrease in cJun with nocodazole and 
an increase in Oct4A/B expression, with bright areas generally becoming very small and 
widely dispersed. A. NT. B. 2h DMSO. C. 4h DMSO. D. 2h nocodazole. E. 4h 
nocodazole. F-J. Comparison of cJun expression with all Oct4 variants (Oct4all). 
Nocodazole appears to increase cJun and Oct4all, but the localization changes. Similarly, 
to Oct4A/B, bright spots of Oct4all signal do seem to correlate to cJun. F. NT. G. 2h 
DMSO. H. 4h DMSO. I. 2h nocodazole. J. 4h nocodazole. Arrows in both images 
indicate a few, but not all, of the areas where co-localization was identified. 
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Table 5. Nocodazole treatments show increased co-localization of cJun with Oct4A, 
but a decrease in co-localization with Oct4all variants. A. Table of Oct4A co-
localization with cJun for each treatment condition. Each row contains the number of co-
localized spots of the total number of spots identified. Co-localized spots were evaluated 
on the Pearson’s and Mander’s coefficients provided by the Zeiss analytical software. 
The Mander’s coefficient is the percentage of overlap between the two channels, while 
the Pearson’s determines the correlation between pixel intensity of the two channels 
(Zinchuk et al. 2007). Very strong Pearson’s values are those greater than 0.85, strong is 
0.85 to 0.49, and moderate is 0.49 to 0.1. Weak and very weak Pearson’s coefficients are 
0.1 to -0.26 and -0.26 to -1. Very strong Mander’s coefficients are ≥0.98, strong are 0.98 
to 0.89, and moderate values are 0.89 to 0.71. Weak and very weak Mander’s coefficients 
are 0.71 to 0.5 and 0.5 to 0. These data were then further defined by combinations of the 
two coefficients to provide a better co-localization picture. The greatest number of co-
localized spots per colony is seen in the 4h nocodazole treatment, but the greatest 
percentage of co-localized spots with at least strong Pearson’s and Mander’s coefficients 
was seen in the 2h nocodazole sample. B. Table of Oct4all co-localization with cJun. 
These data were organized as previously mentioned.  
 
A. 
Oct4A co-localization NT 
2h 
DMSO 
4h 
DMSO 
2h 
Nocodazole 
4h 
Nocodazole 
Very strong Pearson’s 
coefficient (≥0.85) 
4 3 7 21 3 
Strong Pearson’s 
coefficient (≥0.49) 
12 18 9 26 19 
Moderate Pearson’s 
coefficient (≥0.1) 
12 11 14 5 9 
      
Figure 12. Nocodazole has varied affect on cJun and Oct4 protein expression. A-E. 
An example of variation seen between replicates for Oct4A/B. These data exhibit a more 
stark decrease in Oct4A/B and a larger increase in cJun expression. Bright spots of 
Oct4A signal still co-localize with cJun. A. NT. B. 2h DMSO. C. 4h DMSO. D. 2h 
nocodazole. E. 4h nocodazole F-J. An example of the variation seen between replicates 
for Oct4all expression. Both cJun and Oct4all expression are dramatically decreased, but 
the bright spots still co-localize. F. NT. G. 2h DMSO. H. 4hDMSO. I. 2h nocodazole. J. 
4h nocodazole. Arrows in both images indicate a few, but not all, of the areas where co-
localization was identified. 
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Oct4A co-localization NT 
2h 
DMSO 
4h 
DMSO 
2h 
Nocodazole 
4h 
Nocodazole 
Very strong Mander’s 
coefficient (≥0.98) 
26 40 31 56 22 
Strong Mander’s 
coefficient (≥0.89) 
7 3 11 2 2 
Moderate Mander’s 
coefficient (≥0.71) 
0 0 2 0 0 
      
Very strong Pearson’s 
and Very strong 
Mander’s 
3 3 6 21 3 
Very strong Pearson’s 
and Strong Mander’s 
1 0 1 0 0 
Strong Pearson’s and 
Very strong Mander’s 
10 17 5 24 19 
Strong Pearson’s and 
Strong Mander’s 
2 1 3 2 0 
Strong Pearson’s and 
Moderate Mander’s 
0 0 1 0 0 
Moderate Pearson’s and 
Very Strong Mander’s 
8 9 11 5 8 
Moderate Pearson’s and 
Strong Mander’s 
4 2 2 0 1 
Moderate Pearson’s and 
Moderate Mander’s 
0 0 1 0 0 
Weak Pearson’s and Very 
Strong Mander’s 
4 10 8 2 9 
Weak Pearson’s and 
Strong Mander’s 
0 0 1 0 0 
Very Weak Pearson’s and 
Very Strong Mander’s 
1 1 1 4 0 
Very Weak Pearson’s and 
Strong Mander’s 
0 0 4 0 1 
      
Total number of co-
localized spots identified 
33 43 44 58 41 
Total number of cell 
colonies for all images 
40 53 54 66 31 
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B. 
Oct4All co-localization NT 
2h 
DMSO 
4h 
DMSO 
2h 
Nocodazole 
4h 
Nocodazole 
Very strong Pearson’s 
coefficient (≥0.85) 
5 7 1 12 5 
Strong Pearson’s 
coefficient (≥0.49) 
7 6 6 9 17 
Moderate Pearson’s 
coefficient (≥0.1) 
5 5 6 10 23 
      
Very strong Mander’s 
coefficient (≥0.98) 
19 15 12 33 50 
Strong Mander’s 
coefficient (≥0.89) 
0 5 8 6 8 
Moderate Mander’s 
coefficient (≥0.71) 
0 0 0 0 0 
      
Very strong Pearson’s 
and Very strong 
Mander’s 
5 7 1 11 5 
Very strong Pearson’s 
and Strong Mander’s 
0 0 0 1 0 
Strong Pearson’s and 
Very strong Mander’s 
7 4 3 6 16 
Strong Pearson’s and 
Strong Mander’s 
0 2 3 3 1 
Moderate Pearson’s and 
Very Strong Mander’s 
5 3 4 8 17 
Moderate Pearson’s and 
Strong Mander’s 
0 2 2 2 6 
Moderate Pearson’s and 
Moderate Mander’s 
0 0 0 0 0 
Weak Pearson’s and Very 
Strong Mander’s 
2 1 4 7 9 
Weak Pearson’s and 
Strong Mander’s 
0 1 3 0 2 
Very Weak Pearson’s and 
Very Strong Mander’s 
0 0 0 1 2 
Very Weak Pearson’s and 
Strong Mander’s 
0 0 0 0 0 
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Oct4All co-localization NT 
2h 
DMSO 
4h 
DMSO 
2h 
Nocodazole 
4h 
Nocodazole 
      
Total number of co-
localized spots identified 
19 20 20 39 58 
Total number of cell 
colonies for all images 
36 46 27 41 45 
 
Similarly to Oct4A co-localization, Oct4all co-localization to cJun was assessed. 
Generally, there was an increase in cJun and Oct4all with nocodazole treatment and a 
localization more towards the cytoplasm. Again, bright spots appear to be co-localized 
with cJun in the nucleus, but many bright areas that appear to be cytoplasmic co-localize 
with cJun as well (Error! Reference source not found.). In contrast to this, another 
replicate showed a dramatic decrease in Oct4all and a slight decrease in cJun. The bright 
spots still co-localized with cJun and appeared to be mostly in the nucleus. There was 
also a larger increase in cJun and Oct4all for the 4h DMSO samples, which also appeared 
to be cytoplasmic (Error! Reference source not found.). Analysis of the co-localized 
spots across all replicates (n=3) showed that the number of co-localized spots per colony 
increased with nocodazole treatment. Despite this, the degree of co-localization decreased 
with nocodazole treatment. Only 38% of identified co-localized spots in 4h nocodazole 
samples had at least a strong Pearson’s and Mander’s coffecient, while 54% were seen in 
the 2h nocodazole samples and 63% in the NT samples. This would correlate well to the 
data seen with Oct4A, as increases in co-localization of Oct4A with cJun would indicate 
that these two transcription factors have more of a relationship than cJun with other Oct4 
variants.  
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DISCUSSION 
We aimed to better characterize the effects of cJun on Oct4 expression. To 
achieve this, we transiently transfected mES cells with a GFP-cJun construct and a 
transcriptionally inactive L40/42 mutant. Addtionally, we utilized a cytoskeleton 
disrupting drug, nocodazole, to determine if effects of cJun on Oct4 variants would occur 
when endogenous cJun expression was increased under these conditions.  Overall, our 
data indicates overexpression of cJun by both mechanisms affects Oct4 variant 
expression. Previous experiments in our laboratory and the data reported here describing 
increased expression of GATA4 and GATA6 in mESCs ectopically expressing GFP-cJun 
and GFP-L/40/42A suggest these changes in Oct4 affect the potency of mESCs. 
 
cJun Over Expression Produces an Increase in Oct4 Variants and Affects Other 
Pluripotency Markers 
Transfection of cJun increased overall levels of cJun cDNA when analyzed by 
SYBR qPCR chemistry; however, these data were complicated by multiple bands on gel 
analysis and mulitple dissociation peaks. This only occurs in samples transfected with 
either cJun or the L40/42 mutant, suggesting ectopic expression of cJun from the pLVX 
plasmids are creating additional targets recognized by the primers. As the primers produce 
a single band when the purified plasmid is used as template, the most likely cause for 
multiple bands is that the mRNA produced from the plasmid is different than that expressed 
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from the genomic loci. Some bands on the gel which were too close in size to distinguish 
from one another were seen in a few samples which produced only one dissociation peak. 
Further experiments will be needed to fully understand the inconsistency. Plasmid primers 
did produce small additional peaks in the dissociation curves, but they only produced one 
band after agarose gel analysis. Becaue these data were cleaner, the plamid expression was 
used as an indicator of cJun over expression.  
Using a SYBR-based assay, we were able to determine the trends between 
expression of Oct4A, Nanog and Sox2 in relation to the cJun overexpression data. We saw 
a slight increase in expression of all genes in cJun transfected samples. The increase in 
Oct4A gene expression correlates with Western blot analysis of these samples (Brewer 
2018).  The increase in Oct4A gene expression is very similar in the transcriptionally 
inactive L40/42 samples, which suggests perhaps that the MAPK binding that ocurrs at 
those residues to phosphorylate S63 and S73 is not as necessary in this system.  
The exon specific primer/probe analyses showed a larger increase in the the Oct4B 
variants compared to Oct4A expression, which allowed us to better resolve the isoform 
expression differences captured by others in our laboratory who looked at protein 
expression. Protein expression was assessed with a polyclonal antibody generated from a 
recombinantly produced peptide that contains all amino acids of the human Oct4 protein 
that are N-terminal to the POU DNA binding domain. We called Cell Signalling 
Technologies to verify this region contains exon 1 of Oct4A as well as amino acids of 
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Oct4B. When aligning the human and murine protein sequences, the Oct4B amino acid 
sequence is conserved (Figure 13).  
 
A. 
B. 
Figure 13. The polyclonal antibody used to identify Oct4A has some alignment with 
Oct4B. A. A graphical representation of the Oct4B variant transcripts with primers for 
exon 1 (red), exon 2 (blue), and exon 5 (green) denoted by F and R. Additional red boxes 
outline the approximate position in the protein where the antibody would bind. B. 
Alignment of the primary amino acid sequence of the mouse protein with the human 
protein up to the POU domain. 
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The Oct4 variant specific primer-probe assays reveal a large increase in the cDNA 
of Oct4B variants and a decrease in Oct4A. Furthermore, agarose gel electrophoresis reveal 
multiple products generated in each of the transfected sample using exon 2 primers. Some 
are of expected sizes, as the primers should amplify Oct4b, Oct4b’, Oct4b1, b2, and b3 
sequences recently identified by Liu et al (2017), but there are also additional bands. Those 
in samples expressing GFP are smaller and not as distinct.  The cJun samples have a clearer 
band around 400bp and a faint band around 1,00bp. The L40/42 samples analyzed with 
primers to both exon 2 and exon 5 appear to have a  range of large, distinct bands, 
suggesting that loss of phosphorylation of S63/73 affects their expression. One possible 
mode of regulation to explain the increase in products specific to L40/42 expression  is 
through a change in Oct4 mRNA splicing. cJun has previously been shown to particiapte 
in splicing regulation by regulating the transcription of several genes involved in the 
splicing process. The loss of cJun resulted in a change in splicing pattern for 147 genes, 
including 8 involved in cancers and 14 involved in cell death (Katiyar et al. 2012). It would 
be interesting to sequence the additional products, which would reveal whether there are 
additional variant transcripts that have not been identified or if there is aberrant splicing 
occuring, which results in transcripts that differ in intron number and length. Sequencing 
would elucidate whether these sequences contain the probe sequence, which would define 
which bands contribute to the expression data. 
It is also interesting to note that when optimizing the E2 primers, we used cDNA 
from embryoid bodies (EBs) because there was little to no product produced from the 
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cDNA of untransfected mES cells. Since there are changes in Oct4 expression affected by 
cJun over expression, we expect the delicate balance necessary for pluripotency to be 
shifted, as levels of 1.5 fold expression are sufficient to affect cell fates (Niwa et al. 2000). 
There is some evidence that Oct4B variants may have a function in maintaining 
pluripotency as well (Liu et al. 2017).  There is a an increase in  Sox2 gene expression at a 
level that could predict biological significance, as it is highest in cells expressing cJun 
L40/42 when compared to cJun wild type. Though these data indicate that cJun may be 
regulating Sox2 expression directly by binding the promoter, an alignment analysis of the 
Sox2 gene and promoter did not reveal an AP-1 binding site motif; and thus, it is unlikely 
that cJun directly regulates Sox2 expression. An alternative model is that it is the increase 
of Oct4 by cJun that is responsible for this change, as Oct4 has been shown to regulate 
Sox2 expression (Catena et al. 2004).  
Even though none of these data were statistically significant, due to large variability 
and small sample size, the balance of pluripotency markers is very specific. Less than a 
two-fold increase in Oct4 expression can result in the formation of primative endoderm 
and mesoderm (Niwa et al. 2000). Sox2 has been shown to repress mesoderm formation 
(Wang et al. 2012) and a loss of Nanog results in a failure of the blastocyst inner cell mass 
to generate epiblast tissue and ES cells differentiate into extraembryonic endoderm 
(Yamaguchi et al. 2005). Additionally, Nanog maintains pluripotency in the absence of 
LIF (Yamaguchi et al. 2005).  
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cJun Over Expression Directs mESCs Towards an Endoderm Lineage 
If slight changes in pluripotency markers have effects on potency, we would predict 
that there would be an effect on gene expression of germ layer markers affected by slight 
increases in Oct4 expression (Gata4, Gata6) and Sox2, which has been shown to repress 
mesoderm formation (Wang et al. 2012) in these cells. Indeed, we observed larger increases 
in Gata4 and Gata6 expression of NT normalized data. While the differences were a bit 
smaller, GFP normalized data also show the same trend. GFP normalized data showed that 
generally an increase in cJun resulted in an increase in Gata4 and Gata6 expression. When 
cJun overexpression was at its highest (331.3-fold increase), based on pLVXcJun 
amplification, we saw 1.3-fold increase of Gata4 and a 1.2 increase of Gata6.  At the lowest 
pLVXcJun expression (104.9-fold increase), we saw a decrease in both Gata4 and Gata6 
with a 0.75- and 0.79-fold change for Gata4 and Gata6, respectively. The intermediate 
overexpression values of 168.5-fold and 190.4-fold resulted in 1.4-fold and 2.4-fold 
increase of Gata4, respectively. This corresponded to a 2.6-fold and 1.9-fold increase in in 
Gata6, respectively. Western blot analyses performed by others in our laboratory showed 
an increase in Gata4 protein in cJun transfected samples as well (Brewer 2018). 
Biologically, expression of Gata6 precedes Gata4, as Gata6 drives differentiation to 
primitive endoderm and Gata4 marks differentiation into definitive endoderm tissues 
(Plusa et al. 2008; Schrode et al. 2013). Additionally, Gata6 is necessary for primitive 
endoderm formation, as Gata6 negative ICM cells differentiate into mature epiblast tissue 
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prematurely (Schrode et al. 2013). This possibly explains the larger increase in gene 
expression for Gata6.  
The changes in pluripotency markers seen with overexpression of cJun coupled 
with the upregulation of Gata6 suggest cJun could be directing the cells towards -
endoderm. In addition to these data, cardiomyocytes formed from cJun transfected EBs 
exhibited an increased number of beating colonies (Brewer 2018). This supports previous 
research that showed Gata4 expression in embryoid bodies directs these cells towards an 
endoderm fate, which produce cardiac inducing factors and enhance cardiomyocyte 
formation (Holtzinger et al. 2009). This does not exclude the possibility that over 
expression of cJun can be initiating the mechanism through other pathways as an increase 
in cJun and loss of Oct4 are typically indicators for differentiation.  
Other germ layer markers, Brachyury and Sox1, were not as greatly affected by 
cJun over expression. When normalized to GFP the mean expression was similar to NT. 
Interestingly, Sox1 expression normalized to GFP is greatly affected by L40/42 
transfection. Sox1 marks ectodermal lineages and previous data from our lab has shown 
that cJun over expression inhibits proper differentiation of pancreatic islet-like insulin 
secreting clusters with reduced neural network formation, while the L40/42 transfection 
increased both the number of these clusters and the neural projections surrounding them 
(Hosawi 2016). The large increase in Sox1 gene expression is supportive of this data and 
suggests that a decrease in cJun would direct cells towards ectoderm lineages. Additionally, 
Brachyury gene expression was not affected, which correlates with Western blot data that 
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did not show any change in protein expression as well (Brewer et al. in prep). This supports 
the idea that cJun may not be involved in Brachyury regulation at either the protein or the 
transcript level. Taken together, these data indicate that cJun over expression in mES cells 
begins directing cells towards an endoderm progam. 
 
Nocodazole-Induced Expression of cJun Produces a Trend of Increased cJun that 
Affected the Expression of Pluripotency Genes and Oct4 Variants. 
Nocodazole is a cytoskeltal disrupting drug, which can induce alternative tranlation 
of mRNA. It has been shown to increase cJun protein levels by intitating translation at an 
IRES in the cJun 5’ mRNA in human and rat priamry glia, NIH3T3, HEK293T, Cos-7, and 
HeLa cell lines (Polak et al. 2006; Blau et al. 2012). Activation of these mechanisms has 
also shown that cJun protein produced in this manner has different downstream effectors 
than proteins produced through cap-dependent mechanisms. Our results show nocodazole 
treatment of mES cells produced variable expression of cJun. Interestingly, cJun 
expression is also affected by DMSO. The mechanism by which DMSO affects cellular 
function isn’t fully understood and varies between cell type used. However, it has been 
shown it increases differentiation of human embryonic stem cells (hESCs) to definitive 
endoderm through the formation of hepatocytes (Pal et al. 2012; Czysz et al. 2015) and 
there has been some evidence which suggests that DMSO may affect splice sights in vitro 
90 
 
  
(Bolduc et al. 2001). DMSO treatment produced a similar, but less extreme pattern of cJun 
variation. Threfore, there is a nocodazole specific increase in cJun expression.  
As seen in our transient transection assays, the variations in cJun expression 
observed in nocodozole-treated samples associated with variations in gene expression of 
Oct4A, Nanog and Sox2 by SYBR analysis. The variation in expression levels observed 
between replicates may be due to a dosage affect. The increased expression of Oct4 may 
be due to cJun binding the promoter and regulating expression or it may be due to activation 
of the IRES present in Oct4. DMSO also produced an increase in Oct4A expression, but 
this was complicated by one replicate (replicate 3, table 4) producing an additional band 
between 1200bp and 1500bp. This band was not seen in any other sample of the replicate 
and could be due to the alternative translation of cJun.  
The probe-based assays do not show as great an increase in gene expression, 
however the trend holds. Where there is increased cJun due to nocodazole, there is 
increased expression of Oct4A (exon 1) and decreased expression of Oct4B (exon 2). 
Additionally, extra bands were seen with exon 1 primers at about 250bp and 400bp. 
Normalization of all expression data to DMSO maintained the trends seen with NT 
normalized data, but indicates cJun expression from nocodazole may affect Oct4 
expression in a dose dependent manner. For DMSO normalized data, replicate 1 produces 
the highest fold change in expression for cJun at 169.9 and 1.6 for exon 1. Replicate 2 
expressed less than half the level of cJun at 43.1, but has a 2.6 fold increase over DMSO 
for exon 1. Replicate 3 has the lowest cJun expression at 2.6 and produced a fold change 
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of 1.2 for exon 1. These data would indicate that there might be an optimal level of cJun 
expression to increase Oct4A, while others promote other Oct4 variants. This would 
indicate that cJun regulates Oct4A expression, but does not eliminate the possibility that 
nocodazole could regulate protein expression translationally. Western blot analysis was as 
variable as the gene expression and requires further study to determine which mechanisms 
are functioning in this system.  
Gel analysis of the Oct4 primer/probe assays produced similar results to tranfected 
data; multiple unexpected bands were seen. Exon 1, which only produced one band for all 
treatments in the over expression data, had multiple bands for DMSO- and nocodazole-
treated samples. The size of these bands varied between replicate, which is most likely due 
to the variable cJun expression. Bands for replicate 1, which had the highest fold change 
of 169.9, (Figure 10) are at 250bp and 400bp, while bands for replicate 2, which had a fold 
change of 43.1, are only seen in nocodazole samples and are >10,000bp. Additionally 
replicate 3 had a fold change of 2.65 and did not produce any extra bands, except a faint 
300bp band in one triplicate of nocodazole treated sample. Replicate 4 (data not shown) 
showed the most extreme nocodazole response, with extremely bright bands around 500-
600bp (Appendix D and E) Exon 2 primers produced a large range of bands, similar to 
those seen in transfection data and appeared to have a larger variability between replicates. 
All replicates had a 350bp band, like the transfected samples; however, this is not an 
expected amplicon. Additionally there are many bands between 100-350bp that are also 
similar to the transfection data. These regions also encompass the expected amplicon sizes. 
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In addition to these similarities, nocodazole samples occasionally produce a 1500bp, or 
>10,000bp band that correspond to replicates that show similarly large bands in exon 1.  
Interestingly, exon 5 primers show the same trend. The same replicates produce bands 
>10,000bp and between 900-1,000bp. In addition to this, NT samples amplified by exon 5 
primers occasionally produce bands at 250bp, 300bp, or 400bp. DMSO samples 
occassionally have bands at 300bp, while nocodazole samples can have the previously 
mentioned large bands or bands at 300bp and 400bp. All of these bands are similar bands 
seen with cJun and L40/42 transfected samples, except for the extremely large bands seen 
and the additional bands for exon 1, which only produced one band for all transfected 
samples. Despite different mechanisms in increasing cJun expression, there appears to be 
overlap in the bands produced, indicating the effect on Oct4 variants is the same. The 
exceptions to this is the effect on Oct4A and the very large amplicons seen across primer 
sets (Appendix D and E)  
It is possible that increased cJun from activation of the alternative translation 
pathway though nocodazole is affecting the splicing of the Oct4 transcripts such that many 
of the introns are not removed. Others have documented a role for cJun in regulation of 
splicing events. Studies performed in murine mamary epithilium demonstrate cJun 
regulates alternative exon splicing in approximately 147 genes (Katiyar et al. 2011). 
Further study of the Oct4 variants and nocodazole is required to ellucidate the effect 
alternative translation mechanisms may have on gene expression. 
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Given the large changes on Oct4 variants, we would expect the balanced network 
of pluripotency factors to be disrupted. While Oct4A expression is increased in nocodazole 
samples, the transcript levels may be enough to change potency and begin directing cells 
towards a specific fate, much like the spinfection samples. Nanog levels generally 
decreased with increased cJun expression and could be due to changes in expression of the 
other markers, or as a result of nocodazole treatment directly. Nocodazole has been shown 
by flow cytometry to reduce the number of Nanog positive human embryonic stem cells 
(Kallas et al. 2011); however they also saw a decrease in Oct4 positive cells. The authors 
postulated that nocodazole caused a decrease in Oct4, which decreased Nanog and thus 
pluripotency. Discovering how nocodazole affects cJun and the expression of Oct4 variants 
may explain this decrease. Sox2 expression did not appear to be affected by nocodazole 
treatment. These data would appear to contradict the data produced by overexpression of 
cJun through transfection. However, cJun protein produced through alternative translation 
may be regulating expression of different genes and no longer regulates expression of Sox2. 
It is possible that nocodazole could also be initiating alternative translation of the Oct4 
(Guo et al. 2012), which may also have different downstream targets that do not include 
Sox2.  
Unfortunately, we could not determine the effect of nocodazole on germ layer 
expression, as we did with transfection samples, due to an inability to produce EBs in the 
presence of nocodazole. The repeated attempts resulted in large amounts of cell death by 
day 2. However, because gene expression is a relatively quick process, there may be the 
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possibility for a dosing schedule that would reduce cell exposure to the drug and still 
initiate a gene expression programs. Further studies will be needed to determine if these 
trends in gene expression of pluripotency markers results in a specific differentiation 
program. As there are many redundancies in cell signalling and many interconnecting parts 
of this system that are still unknown in ES cells, it is difficult to draw any conclusions 
beyond the general trends seen. 
Nocodozole-Induced Changes in cJun and Oct4 Expression Co-localize to the Same Cells 
Nocodazole treatment produced a varied response in protein expression by ICC 
analysis as well. The increases in cJun and either Oct4A or Oct4all varied from mild to 
large and varied within and between replicates. As each replicate was performed at 
different times and with different batches of nocodazole, it is possible the variation is 
from that. Despite this, there is a general trend consistant across all replicates. Bright 
spots of Oct4A or Oct4all generally co-localize in the same cell as those with high levels 
of cJun expression. cJun is not always the brightest at these spots, but it is there. Analysis 
of co-localized spots using the Zeiss software supports this trend. Evaluation of co-
localization by Pearson’s and Mander’s coefficient shows that 2h nocodazole treatment 
produced the strongest cellular co-localization of Oct4A/B with cJun and 4h nocodazole 
treatment showed stronger co-localization than NT. However, there were a larger number 
of co-localized spots per colony for 4h nocodazole treated samples than 2h nocodazole.  
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Previous work demonastrated that nocodazole induces an increase in cJun mRNA 
30 minutes post treatment; however, following this, there is no increase in mRNA for the 
following 24h in HeLa cells. Despite this, cJun protein increased over 24h (Polak et al. 
2006). Our nocodazole samples were harvested 2h post nocodazole treatment and did 
show an increase in cJun transcript, which appears to contradict the previous findings. 
This could be explained by the transcriptional activity of mES cells, which are in a more 
transcriptionally active state. Because of this, mESCs may be more susceptible to gene 
expression changes or possibly more sensitive to the cytoskeletal disruption induced by 
nocodazole. Additionally, because of the more permissive chromatin structure and 
increased cJun, it is possible the increase in cJun cDNA expression seen might be due to 
regulation of its own promoter.  
The number of cellular co-localization/colony also increased in cells examined 
with an antibody recognizing all isoforms of Oct4 (Oct4 all), but the degree of co-
localization decreased with nocodazole treatment compared to NT. There was a higher 
degree of co-localization with 2h nocodazole samples, compared to 4h treatment. While 
the number of co-localized spots did not appear to increase with colony number, colony 
size was not taken into account and may be correlated. There appears to be a very 
tentative relationship between nocodazole and Oct4A co-localization with cJun versus 
Oct4all co-localization with cJun 2h after nocodazole treatment. In this treatment, the 
Oct4A/B co-localization increased, while Oct4all co-localization decreased. It is not at all 
a definitive relationship, but may indicate a trend that further testing would reveal. It 
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would also support the transcriptional data we saw. Generally speaking, there is an 
increase in co-localization of Oct4A/B/B1 with cJun in the same cell following 
nocodazole treatment, which is supported by transcript data via probe based assays. 
Additionally, the inconsistencies seen with ICC and Western blot analysis seem to 
correlate with the large variation seen in transcript data. 
In addition to co-localization, we observed a few other trends with nocodazole 
treatment. While the sub-cellular localization of these proteins cannot be validated on our 
microscope, cJun expression appears to be more cytoplasmic 4h after nocodazole 
treatment. Oct4all also demonstrated this pattern and cytoplasmic localization of Oct4B 
variants has been shown previously with genotoxic, heat, and cell stress (Wang et al. 
2009; Gao et al. 2012).  
Generally, all co-localized spots had at least a strong Mander’s coefficient. The 
Pearson’s coefficient was more distributed from very weak co-localization to very strong. 
However, generally very few co-localized spots fell into the weak or very weak category. 
This indicates there is a large portion of overlap between these signals in general, but a 
more variable correlation in relative signal intensity. Further studies on the effect of 
nocodazole on the co-localization of cJun with Oct4 variants could include the use of a 
microscopy that images samples in slices, which would help account for the overlap. 
Because cell colonies are 3D structures, but our images are not, we cannot determine 
whether signal overlap is in the same Z plane. The use of confocal microscopy in 
conjunction with deconvolution software and the antibody techniques we utilized could 
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improve resolution. Additionally, transmission electron microscopy could be utilized 
with stains for specific organelles or structures and gold-labeled anitbodies to identify 
these proteins at more precise locations within a single cell.
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CONCLUSIONS 
cJun is an important transcription factor in development. Previous work has 
shown cJun inhibits expression of genes important to pluripotency, like Sall4 and Nanog, 
and upreulates expression of Gata4 and Gata6 (Liu et al. 2015). Generally an increase in 
cJun has marked a decrease in pluripotency, but the Oct4 promoter contains an AP-1 
binding site that appears to allow cJun regulation of Oct4 variants, including the potency 
marker Oct4A.  
Through overexpression of cJun by transiently transfecting mES cells, we 
determined that cJun may regulate the expression of Oct4 variants, with the strongest 
change in Oct4B variants. That we saw a larger increase in these variants with the 
transcriptionally inactive L40/42 mutant indicates there may be an alternative splicing 
mechanism activated by cJun overexpression. An increase was also seen for Sox2 with 
this mutant, indicating a potential mechanism for cJun regulation of Sox2 through Oct4A. 
With these samples, we were also able to determine that overexpression of cJun drives 
mES cells toward an endoderm lineage and the L40/42 mutant may drive mES cells 
towards an ectodermal lineage. The upregulation of Gata4 correlates with cJun 
overexpression and the culmination of these data support previous works that show Gata4 
expression in EBs increases cardiomyocyte formation by producing specific endoderm 
lineages that generate cardiac inducing factors.  By using nocodazole to induce cJun 
expression we determined that cJun gene expression is increased by drug treatment and 
that cJun protein increased by nocodazole co-localizes strongly with Oct4A/B at 2h post 
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treatment and not as strongly with other Oct4 variants. More work will be necessary to 
determine the exact mechism by which cJun cDNA is increased  versus protein 
expression using nocodazole stimulation and how that might affect Oct4 gene and protein 
expression, as well as potency. Additionally, we were able to determine that additional 
bands are produced from Oct4 variants with nocodazole and DMSO that were not seen 
with transfected samples. Although more work is required to determine the identity of the 
Oct4 variants produced, cJun appears to regulate expression of all Oct4 variants.  
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APPENDIX A
Appendix A: Whole electrophoresis gels used in Figure 4, 5, and 8. A. gel of Gapdh 
and Sox2 primers amplifying cDNA from mESCs. Gapdh was used in Figure 5, but this 
Sox2 set was not used. B. Gel of Nanog and pLVXcJun amplified cDNA used in Figure 
5. C. Gel of Sox2 used in Figure 5. D. Gel of Oct4A primers amplifying genomic and 
cDNA. E. Gel of Gata4 and Gata6 amplification of cDNA used in Figure 8. Lanes 1, 2, 
and 6 are Gata6 and 3, 4, and 5 are Gata4. F. Gel of Sox1 and Brachyury amplification of 
cDNA used in Figure 8. G. Gel of cJun amplification of cDNA used in Figure 5. H. Gel 
of cJun and pLVXcJun amplification of transfection samples used in Figure 4. I. More 
extreme example of multiple bands produced by cJun amplification of transfection 
samples. Used in Figure 4. 
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 APPENDIX B  
Appendix B: Primers used for RT-qPCR. The primer name, sequence, expected amplicon size, annealing temperature 
used, and qPCR efficiency data, 𝒓𝟐, slope and efficiency are given. Primers for cJun, Sox2, Nanog, Oct4A (exon 1), and 
Oct4all (exon 2 and exon 5) allowed us to assess the effect of cJun overexpression or nocodazole treatment on pluripotency 
and endogenous cJun transcription. The pLVXcJun primers allowed us to remove over expressed GFP-cJun mRNA from 
endogenous cJun expression in cells transfected with the GFP cJun construct and determine the autoregulatory effects of cJun 
on its own gene expression. Gapdh is a constitutively expressed control gene to account for unknown template concentrations. 
Brachyury, Gata6, Gata4, and Sox1 expression provided information on whether changes in cJun expression initiate a 
differentiation program to a specific germ layer. Efficiencies determined the equation used to analyze the expression data. The 
Pffafl equation (2−∆∆𝐶𝑡) (Pfaffl 2004) requires that primer efficiencies be equal for the experimental gene as well as the control 
gene. The efficiencies below are different and analysis required a variation of the Pffafl equation which accounts for 
differences in primer efficiency. Expected base pair values marked with an asterisk denote the probe-based assays which 
produced other unexpected bands upon gel analysis. 
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Gene Sequence 5' to 3' Expected 
bp 
Annealing 
temp (°C) 
𝑟2 Slope Efficiency Citation 
cJun-R CACCTGTTCCCTGAGCATGTT 118 60 0.969737 -
3.170345 
1.067393207 Sprowles 
unpublished 
cJun-F CTCCAAGTGCCGGAAAAGGAA       
Nanog- R AGGGTCTGCTACTGAGATGCTCTG 364 61 0.994614 -
3.466201 
0.943122998 (Chen et al. 2012) 
Nanog- F CAACCACTGGTTTTTCTGCCACCG       
Gapdh-R CGAGTTGGGATAGGGCCTCTCTTGC 230 63 
61 
60 
0.902912 
0.952598 
0.839916 
-
2.874308 
-
2.973768 
-
3.133186 
1.227972507 
1.169070714 
1.085277915 
(Chen et al. 2012) 
Gapdh-F GGTTGTCTCCTGCGACTTCAACAGC       
Sox2-R TGCTGCGAGTAGGACATGCTGTAGG 207 63 0.974698 (-
)3.87294 
0.812181863 (Chen et al. 2012) 
Sox2-F GCACATGAACGGCTGGAGCAACG       
Oct4A 
exon 1-R 
CCTCCTCTGAGCCCTGT 111bp 60 0.929277 
For 
SYBR: 
0.981957 
-
3.481575 
For 
SYBR: -
3.694379  
0.9374313692 
For SYBR: 
0.8650113822 
IDT predesign 
qPCR assays 
Oct4A 
exon 1-F 
AACTGTTCTAGCTCCTTCTGC       
Oct4A 
probe 
TGGTTCCACCTTCTCCAACTTCACG       
Oct4all 
exon 2-R 
GGTGATCCTCTTCTGCTTCAG 91, 296, 
297  
60 0.945009 -
3.145305 
1.079381572 IDT predesign 
qPCR assays 
Oct4all 
exon 2-F 
CAGATAGGAACTTGCTGGGT       
Oct4all 
exon 2 
probe 
CTGTTCTAGCTCCTTCTGCAGGGC       
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Gene Sequence 5' to 3' Expected 
bp 
Annealing 
temp (°C) 
𝑟2 Slope Efficiency Citation 
Oct4all 
exon 5-R 
GTAGCCTCATACTCTTCTCGTTG 135, 274 60 0.988651 -
3.209814 
1.049012142 IDT predesign 
qPCR assays 
Oct4all 
exon 5-F 
CCTACAGCAGATCACTCACAT       
Oct4all 
exon 5 
probe 
TCGAACCACATCCTTCTCTAGCCCA       
pLVX 
cJun-R 
TTGAGGGCATCGTCGTAGAAG 70 61    Sprowles 
unpublished 
pLVX 
cJun-F 
CACTAGTGATTGCGGGCC       
Sox1-R TTGAGCAGCGTCTTGGTCTTG 134 60 0.9876 -
3.276507 
1.019310351 (Yan et al. 2013) 
Sox1-F GCCGAGTGGAAGGTCATGTC       
Brachyury-
R 
TGCGTCAGTGGTGTGTAATGTG 117 63 0.975551 -
3.298003 
1.010082087 (Bernardo et al. 
2011) 
Brachyury 
F 
TCTCTGGTCTGTGAGCAATGGT       
Gata4-R ACCAGGCTGTTCCAAGAGTCC 225 63 0.940442 -
3.264471 
1.024549247 (Hu et al. 2013) 
Gata4-F CAGCAGCAGCAGTGAAGAGATG       
Gata6-R GCCAGAGCACACCAAGAATCC 182 63 0.883441 -
3.733367 
0.852911716 (Poh et al. 2014) 
Gata6-F TCTACACAAGCGACCACCTCAG       
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APPENDIX C 
Appendix C: Whole gel images of Oct4 amplification of transfection samples. A. and 
B. are gels of exon 1 amplification of spinfection samples for all 4 replicates. C-E. Gels 
of exon 2 amplification of transfection samples. F-G. Gels of exon 5 amplification of 
transfection samples.  
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APPENDIX D 
Appendix D: Whole gel analysis of nocodazole treated samples reveals inconsistency 
between replicates. A. Gel of exon 1 amplification of drug treated samples. B. Gel of 
exon 5 amplification of drug treated samples. C. Gel of exon 2 amplification of drug 
treated samples. 
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APPENDIX E 
Appendix E: Table of Oct4 predicted bands, additional bands and treatment. This 
table highlights some of the variability in Oct4 expression seen with nocodazole 
treatment. 
 
Primer set Expected bands Bands present Treatment 
Exon 1 1 band-111bp 111bp 
200bp 
400bp 
600-700bp 
>10,000 
All 
Nocodazole 
DMSO 
Nocodazole 
Nocodazole 
Exon 2 Oct4b’: 91bp 
Oct4b2 and 3: 296bp  
Oct4b and b1: 297bp 
91bp-possibly 
296-297bp 
550bp 
Multiple 90-250 
1,200-1,500bp 
>10,000 
All 
All 
DMSO 
All 
Nocodazole 
Nocodazole 
Exon 5 Oct4A, Oct4b’, Oct4b 
and Oct4b1: 135bp  
Oct4b2 and 3: 274bp 
135bp 
274bp 
250bp 
300/350bp 
400/450bp 
 
900-1,000bp 
>10,000bp 
 
All 
NT and some DMSO 
Some NT 
All but inconsistently 
Some NT and some 
nocodazole 
Some nocodazole 
Some nocodazole 
 
